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ABSTRACT 
 
Bone tissue can spontaneously heal through a characteristic, complex, and 
highly regulated process of consecutive and closely linked stages of inflammation, 
repair and remodelling. Trauma, extensive bone loss, systemic inflammation, and 
multiple diseases may disrupt this process, impair healing and result in non-union 
and bone defects. Osteoporosis is increasing in the progressively older population of 
western countries. As it results in loss of mineralization and subsequent changes in 
bone architecture, related fractures and bone loss can be anticipated. The 
management of fractures and bone defects, especially in osteoporotic conditions, 
remains a significant surgical challenge. Autologous grafts are still considered the 
current gold standard for bone tissue replacement but are also associated with 
significant problems and insufficiencies. Accordingly, tissue engineering has been 
focusing on developing bone substitutes that can withstand normal dynamic 
physiological mechanical stresses and provide a matrix capable of supporting cell 
migration and tissue ingrowth. 
In this doctoral dissertation we aim to contribute to the development of 
alternative injectable biomaterials to be used in the management of bone defects, 
particularly adapted to the osteoporotic patient. 
First we assessed the in vivo efficacy and safety of strontium (Sr) enriched 
biomaterials in bone formation and/or remodelling. There is considerable evidence 
that Sr has a beneficial influence in bone strength and architecture, and incorporating 
Sr in biomaterials is a strategy to locally improve osteogenesis without inducing 
detrimental side effects. With this purpose, we conducted a systematic review on the 
effect of Sr-enriched biomaterials on bone remodelling, when compared to Sr-free 
similar ones. 27 papers were included, and all showed similar or increased effect of 
Sr in bone formation and/or regeneration, in both healthy and osteoporotic models, 
an effect impacted by time and concentration. Only one article reported systemic 
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effects from Sr addition. This review, the first of its kind on this subject, confirmed the 
safety and effectiveness of Sr-enriched biomaterials for stimulating bone formation 
and remodelling in animal models. However, the wide range of study methods 
impaired an adequate quantitative synthesis of the results. 
In the second part we describe the development and characterization of a 
hybrid polymer-ceramic injectable system that consists of an alginate matrix cross-
linked in situ in the presence of Sr, and Sr-rich hydroxyapatite microspheres. 
Different formulations were tested for injectability and mechanical properties. A 3.5% 
(w/v) ultrapure sodium alginate solution was used as the vehicle and its in situ 
gelation was promoted by the addition of calcium or Sr carbonate, and Glucone-δ-
lactone. Compositions with 35% w of 555 µm microspheres presented the best 
compromise between injectability and compression strength of the system. Micro-CT 
analysis revealed a homogeneous distribution of the microspheres inside the vehicle, 
and a mean inter-microspheres space of 220 µm, adequate for tissue and vascular 
ingrowth. 
Finally we evaluated the in vivo response to this Sr-enriched system and its 
influence on new bone formation compared to a similar Sr-free material. Both 
systems were injected in a critical-size metaphyseal femoral bone defect rat model 
and results were assessed at 15 and 60 days post surgery. Micro-CT results show a 
trend towards higher new bone formed in Sr-hybrid group. Greater cell invasion was 
detected at the center of the defect of Sr-hybrid group after 15 days with earlier bone 
formation. Higher material degradation with increase of collagen fibers and bone 
formation in the center of the defect after 60 days was observed, as opposed to bone 
formation restricted to the periphery of the defect in the control. These imaging and 
histological findings support the evidence of an improved response with the Sr 
enriched material. Moreover, no alterations were observed in the Sr levels in 
systemic organs or serum.  
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In conclusion, this thesis: (I) confirms the effectiveness and safety of Sr-
enriched biomaterials for bone regeneration; (II) develops an alternative viscoelastic 
biomaterial for the management of bone defects, which can be manually injected, 
sets in situ, and offers structural support and a temporary scaffold for bone growth; 
(III) provides additional evidence of enhanced bone formation with the incorporation 
of Sr on the biomaterial, without detrimental systemic effects. 
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RESUMO 
 
O tecido ósseo tem a capacidade de regeneração através de um processo 
característico, complexo e altamente regulado, envolvendo fases consecutivas e 
intimamente ligadas de inflamação, reparação e remodelação. O trauma, perda 
óssea significativa, inflamação sistémica e múltiplas doenças podem alterar este 
processo, impedir a reparação, e resultar em não união e defeitos ósseos. A 
osteoporose está a aumentar na população cada vez mais envelhecida dos países 
ocidentais. Uma vez que desta doença resulta uma perda da mineralização e 
subsequentes alterações da arquitetura óssea, são de esperar fraturas e perdas 
ósseas. O tratamento das fraturas e defeitos ósseos, especialmente em condições 
osteoporóticas, permanece um desafio cirúrgico significativo. Os enxertos autólogos 
são ainda considerados o padrão para a substituição do tecido ósseo, mas estão 
associados a problemas e insuficiências relevantes. Consequentemente, a 
engenharia de tecidos tem-se focado no desenvolvimento de substitutos ósseos que 
possam suportar as forças mecânicas dinâmicas fisiológicas e fornecer uma matriz 
capaz de suportar a migração celular e a invasão tecidular. 
Nesta dissertação doutoral procuramos contribuir para o desenvolvimento de 
biomateriais injetáveis alternativos para o tratamento de defeitos ósseos, 
particularmente adaptados ao doente osteoporótico. 
Começámos por avaliar a eficácia e segurança in vivo de materiais 
enriquecidos em estrôncio (Sr) na formação e/ou remodelação ósseas. Há evidência 
considerável que o Sr tem uma influência benéfica na resistência e arquitetura 
ósseas, e a incorporação de Sr em biomateriais é uma estratégia para melhorar a 
osteogénese localmente sem induzir efeitos laterais deletérios. Neste sentido, 
realizámos uma revisão sistemática sobre a evidência que compara o efeito de um 
material enriquecido em Sr na regeneração óssea quando comparado com um 
material semelhante livre de Sr. Foram incluídas 27 publicações, e todos os estudos 
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mostraram um efeito similar ou acrescido do Sr na formação e/ou regeneração 
óssea, tanto em modelos saudáveis como osteoporóticos. Este efeito é 
positivamente influenciado pelo tempo e pela concentração. Apenas um artigo 
reportou um efeito sistémico resultante da adição de Sr. Esta revisão, a primeira do 
género, confirmou a segurança e eficácia de biomateriais enriquecidos em Sr na 
formação e remodelação ósseas em modelos animais. Contudo, a elevada 
variabilidade dos métodos de estudo impediu uma síntese quantitativa adequada 
dos resultados.  
Na segunda parte descrevemos o desenvolvimento e caracterização de um 
sistema híbrido polímero-cerâmico injetável que é formado por uma matriz de 
alginato reticulada in situ na presença de Sr, e microesferas de hidroxiapatite ricas 
em Sr. Foram testadas diferentes formulações quanto à injectabilidade e 
propriedades mecânicas. Uma solução de alginato de sódio ultrapuro a 35% (w/v) foi 
usada como veículo e a gelação in situ foi promovida pela adição de carbonato de 
cálcio ou Sr, e glucono-δ-lactona. As composições com 35% de microesferas de 555 
µm apresentaram o melhor compromisso entre injectabilidade e força de 
compressão do sistema. A análise por Micro-CT revelou uma distribuição 
homogénea das microesferas dentro do veículo, e um espaçamento médio entre as 
mesmas de 220 µm, adequado para invasão tecidular e vascular. 
Por último, avaliámos a resposta in vivo a este sistema e a sua influência na 
formação de novo osso comparadas com um material similar livre de Sr. Ambos 
sistemas foram injetados num modelo de defeito ósseo metafisário femoral crítico de 
rato, e os resultados avaliados aos 15 e 60 dias após a cirurgia. Os resultados do 
Micro-CT mostraram uma tendência para formação acrescida de novo osso no 
grupo do híbrido de Sr. Foi detetada uma maior invasão celular no centro do defeito 
no grupo do híbrido de Sr aos 15 dias com formação óssea mais precoce. Foi 
observada uma maior degradação do material com aumento de fibras de colagénio e 
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formação óssea no centro do defeito aos 60 dias, enquanto que no controlo a 
formação óssea se limitou à periferia. Estes achados imagiológicos e histológicos 
confirmam a evidência de uma melhor resposta com material enriquecido em Sr. 
Adicionalmente, não foram observadas alterações nos níveis séricos de Sr ou em 
órgãos sistémicos. 
Em conclusão, esta tese: (I) confirma a eficácia e segurança de biomateriais 
enriquecidos em Sr utilizados para regeneração óssea; (II) desenvolve um 
biomaterial viscoelástico alternativo para o tratamento de defeitos ósseos que pode 
ser injetado manualmente, reticula in situ e garante suporte estrutural e uma matriz 
temporária para crescimento ósseo; (III) fornece evidência adicional de melhoria da 
formação óssea com a incorporação de Sr no biomaterial, sem efeitos sistémicos 
deletérios. 
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Bone tissue has the ability to spontaneously heal through a characteristic, 
complex, and highly regulated process with consecutive and closely linked stages of 
inflammation, repair and remodeling [1]. However, disruption of this process caused 
by trauma, extensive bone loss, systemic inflammation, such as in diabetes mellitus, 
sepsis and rheumatoid arthritis, and diseases like cancer and osteoporosis, can 
impair healing and result in non-union and bone defects [1]. As the expectancy of life 
rises in western countries, an increase in the prevalence of osteoporosis, related 
fractures and bone loss can be anticipated. The management of fractures and bone 
defects, especially in osteoporotic conditions, remains a significant surgical challenge 
and there is a need for improved tissue engineering strategies with either biological 
or synthetic bone substitutes [2, 3].  
This introduction will focus the problems and drawbacks of currently used bone 
grafts and substitutes, the experience with ceramics and hydrogels, and the potential 
benefits of doping biomaterials with other elements, especially with strontium. 
 
Bone grafts 
Autologous grafts are considered the current gold standard for bone tissue 
replacement because of easy harvest, osteogenic potential and long record of 
successful use in clinical practice. Nevertheless, autografts are limited in supply, 
need an additional time-consuming harvest surgery, with associated morbidity, pain 
and poor cosmetic appearance at the donor site, and their properties, shape and size 
do not exactly match those of the bone to be replaced [4-6]. Allografts and xenografts 
have also been extensively studied but the risks of immune rejection and disease 
transfer have limited their use [4].  
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Bone substitutes 
In order to overcome the problems with bone grafts, alternative bone 
substitutes, including hard and soft biomaterials, have been introduced for bone 
tissue engineering. Ideally, a bone substitute should conform to Giannoudis’ 
‘‘Diamond theory’’ where osteogenic cells and vascularization, mechanical stability, 
growth factors, and osteoconductive scaffolds, are a prerequisite for adequate bone 
healing [7]. It should also be sterilizable, easily handled and molded into the bone 
defect, radiolucent for prompt radiographic assessment, and readily available, with 
minimal morbidity, at a reasonable cost [3, 4]. None of the bone substitutes available 
fulfills yet all the necessary requirements for each clinical situation.  
 
Ceramic bone substitutes 
Ceramic substitutes have been used for decades and present several 
advantages, notably adequate biological response, osteoconductivity and 
mechanical properties [8-10]. Hydroxyapatite (HA), the primary mineral component of 
teeth and bone, can be used either alone or in combination with tricalcium phosphate 
(TCP) to produce blocks and granules [11, 12]. Combining the two allows an 
adequate balance between the rapid degradation of TCP and the high mechanical 
strength of HA, for optimal bone substitution [4].  
Ceramic micro or nanoparticles can be suspended in appropriate vehicles to be 
used as injectable materials [13-15]. They can be applied by minimally invasive 
surgical procedures effectively filling irregularly shaped cavities, with reduced tissue 
damage and limited exposure to infectious agents. Spherical particles are more 
suitable for implantation than non-homogeneous granules, since they conform better 
to irregular implant sites and present more predictable flowing properties during 
injection [16-19]. Still, handling and brittleness of calcium phosphate cements are 
frequently cited limitations [20, 21]. 
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Scaffold porosity is essential to support differentiation of cells into bone forming 
osteoblasts, migration of bone progenitor cells, and ingrowth of blood vessels and 
nerves, to repair the defect site [22, 23]. It has been suggested that a minimum pore 
size of ~100-150 microns is necessary for bone formation, and at least 300 microns 
for vascular ingrowth [23]. Although increased porosity improves biological response, 
at the same time mechanical properties may be compromised. 
Another challenge for bone substitutes is the resorption rate, as they are 
expected to be progressively substituted by newly formed bone [24]. A very fast 
degradation rate will not allow sufficient support for adequate cell invasion, whereas 
if too slow, this invasion may actually be impaired, both resulting in failure. 
 
Hydrogels in bone tissue engineering 
Because of their biocompatibility both natural and synthetic polymers have also 
been used for bone tissue engineering, either as solid scaffolds or hydrogels. 
Hydrogels are water-swollen, networked, hydrophilic polymeric materials, typically 
formed via cross-linking or chain entanglement, that maintain a distinct three-
dimensional structure [25, 26]. They have been shown to support cell culture within 
the gel and on its surface, and to increase angiogenesis and osteoconductivity in 
different bone repair models [27-30]. However, hydrogels, as soft materials, have an 
elastic modulus inferior to that of bone, significantly limiting their use in load bearing 
areas [31]. Nevertheless, the number of cross-links, type of monomer, and local 
environment can be adjusted to modify mechanical properties [32]. 
An emerging trend is combining hydrogels with other materials, resulting in 
hybrid composites that mimic both the organic and inorganic phases of natural bone. 
Combined with ceramic granulates they form moldable pastes and putties through 
improved cohesion, and can also be used as carriers for injectable composites [31, 
33]. Hydrogels, can thus form a three dimensional environment with the suspended 
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ceramic particles, providing support and modulating cell invasion for bone tissue 
repair [31]. 
 
Alginate 
Alginate is a natural polymer composed of guluronic and mannuronic acids, 
found in seaweeds and typically extracted from brown algae (Phaeophyceae). It is 
considered to be biocompatible, non-toxic, non-immunogenic and biodegradable, 
and is easily extracted at low price, making it adequate for biomedical applications 
[34, 35]. Alginate has the ability to form hydrogels under mild chemical conditions, in 
the presence of divalent cations, such as Ca2+, Ba2+ and Sr2+, through a 
cytocompatible physical gelation process. These cations bind homoguluronic blocks 
in adjacent alginate chains in a cooperative manner (egg-box model) producing a 
cross-linked hydrogel network [36].  
Both biodegradability and mechanical properties can be tuned by using varied 
ratios of different molecular weights [34, 37]. Besides, alginate can be combined with 
inorganic materials like HA to improve mechanical strength and bone tissue 
formation, or be used as a carrier for ceramic components, as an injectable system, 
taking advantage of its in situ gel forming ability [38-40]. In situ gelation allows easy 
injection through minimally invasive procedures, while providing cohesion and 
resistance to washing-out at the implant site. Different particle size and shape, 
polymer concentration, and sterilization can influence both injectability and 
mechanical properties [31]. Low viscosity allows easier injectability, but induces 
greater particle sedimentation, and filtering, with phase separation upon injection. 
This can be minimized by smaller particle size, higher viscosity, high liquid to powder 
ratio, quicker extrusion, small syringe size, and use of short cannula [31, 41]. 
However, carriers featuring excessive rigidity and lack of degradation exhibit 
decreased bioactivity, delaying cellular colonization, impairing vascularization, and 
directing bone healing away from an endochondral pathway [31, 42].  
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A strategy to promote cellular infiltration within the hydrogel and to direct de 
novo bone formation at the local implant site is the incorporation of bio-adhesive 
motifs derived from extracellular matrices into alginate. Covalently binding of the 
RGD (arginine-glycine-aspartic acid) sequence onto alginate promotes osteogenic 
cell adhesion, focal adhesion formation, proliferation, and differentiation [43].   
Other advantages of alginate are its potential use as a controlled release 
vehicle of enzymes, drugs and cytokines, and its ability to encapsulate and deliver 
cells that support natural tissue regeneration [44-48]. 
 
Strontium 
Strontium (Sr) is a trace element that plays a dual role in bone metabolism, 
simultaneously stimulating bone formation and inhibiting bone resorption [49-54]. At 
least three mechanisms have been implicated in these opposite effects of Sr: 
activation of the calcium-sensing receptor (CaSR), nuclear factor of activated Tc 
(NFATc)/Wnt signaling, and modulation of osteoprotegerin (OPG) and receptor 
activator of nuclear factor κ-B ligand (RANKL) [49]. Several in vitro studies have 
shown that Sr decreases bone resorption, by reducing osteoclast activity [55-57], 
decreasing functional osteoclast markers expression [55], disrupting osteoclasts 
cytoskeleton [56], and increasing osteoclast apoptosis [58]. Simultaneously, it 
induces positive effects on osteoblastogenesis and osteoblast activity in different in 
vitro models [59], namely by enhancing replication of preosteoblastic cells [56, 60-
63], increasing osteogenesis [56, 60, 64-66], decreasing osteoblast apoptosis [61, 
67], and promoting terminal differentiation of osteoblasts into osteocytes [60]. 
Pre-clinical in vivo studies confirm in vitro data showing the beneficial effect of 
Sr on bone formation and remodeling in both normal and osteopenic/osteoporotic 
animal models [50, 68-73]. 
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Sr, administered orally as Sr ranelate has been in clinical use as an effective 
anti-osteoporotic drug in the prevention of both vertebral and non-vertebral 
osteoporotic fractures [49, 74, 75].  
However, cardiovascular safety of oral intake of Sr ranelate has been 
questioned due to a small but significant increase in non-fatal myocardial infarctions 
[76-78]. 
According to current strict guidelines [78], the drug is authorized for the 
treatment of severe osteoporosis, in postmenopausal women and in adult men, at 
high risk of fracture for whom treatment with other medicinal products approved for 
the treatment of osteoporosis is not possible. Additionally, its use should be restricted 
to patients with no past or current history of ischemic heart disease, peripheral 
arterial disease and/or cerebrovascular disease or uncontrolled hypertension. 
Doping calcium phosphate cements and other ceramics with bioactive drugs is 
a recent trend to improve their regeneration potential. Incorporating Sr in biomaterials 
is a strategy to achieve high concentrations in a local environment, using the Sr 
osteoanabolic and anti-osteoclastic properties to enhance new bone formation, while 
avoiding its systemic effects [79-81]. These composite hybrid enriched biomaterials 
may lead to improved results in the management of bone defects in osteoporosis. 
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Aims of the Thesis 
The main objective of this PhD thesis is the development of strontium enriched 
injectable materials to be used in the management of bone defects, particularly 
adapted to the osteoporotic patient. 
 
Thereby, the following specific objectives were defined:  
1) Assess the in vivo efficacy and safety of Sr enriched biomaterials in bone 
formation and/or remodeling  
A systematic review on evidence that compares the effect of a Sr-enriched and 
a similar Sr-free biomaterial was conducted in PubMed and Scopus. Data showed 
increased bone formation and remodeling with the use of biomaterials enriched with 
Sr, an effect impacted by time and concentration, with adequate safety. These 
results are presented in Chapter II. 
 
2) Development and characterization of a new injectable biomaterial to be used for 
bone regeneration 
Following previous works carried out by our group, an injectable hybrid system 
that consists of an alginate matrix cross-linked in situ with Sr, reinforced with Sr-rich 
hydroxyapatite microspheres, was developed. Different formulations were tested for 
injectability and mechanical properties. These results are described in Chapter III. 
 
3) Evaluate the in vivo response to the Sr enriched hybrid system and its influence 
on new bone formation compared to a similar Sr-free material  
Both systems were injected in a critical-size metaphyseal femoral bone defect 
rat model and results were assessed at 15 and 60 days post surgery. Micro CT and 
histological findings support the evidence of an improved response with the Sr 
enriched material. Moreover, no changes were observed in Sr levels in systemic 
organs or serum. These findings are presented in Chapter IV  
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Abstract 
Objectives 
This systematic review aimed to assess the in vivo and clinical effect of strontium 
(Sr)- enriched biomaterials in bone formation and/or remodelling. 
Methods 
A systematic search was performed in PubMed, followed by a two-step selection 
process. We included in vivo original studies on Sr-containing biomaterials used for 
bone support or regeneration, comparing at least two groups that only differ in Sr 
addition in the experimental group. 
Results 
A total of 572 references were retrieved and 27 were included. Animal models were 
used in 26 articles, and one article described a human study. Osteoporotic models 
were included in 11 papers. All articles showed similar or increased effect of Sr in 
bone formation and/or regeneration, in both healthy and osteoporotic models. No 
study found a decreased effect. Adverse effects were assessed in 17 articles, 13 on 
local and four on systemic adverse effects. From these, only one reported a systemic 
impact from Sr addition. Data on gene and/or protein expression were available from 
seven studies. 
Conclusions 
This review showed the safety and effectiveness of Sr-enriched biomaterials for 
stimulating bone formation and remodelling in animal models. The effect seems to 
increase over time and is impacted by the concentration used. However, included 
studies present a wide range of study methods. Future work should focus on 
consistent models and guidelines when developing a future clinical application of this 
element. 
 
Keywords: Biomaterials, Strontium, Bone 
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Introduction  
The treatment of fractures carries important challenges, especially when 
impaired bone healing or bone loss is present. Osteoporosis is increasingly found in 
Western countries as the population ages, leading to a significant rise in the 
incidence of specific fractures, where these problems are particularly evident [1]. 
New treatment options are needed to overcome the challenges associated with 
management of this condition.  
Biological and synthetic bone grafts have been used to manage bone defects, 
and autografts are the current benchmark [2]. However, due to their limited 
availability, the morbidity associated with harvest surgery and the relatively poor 
performance of synthetic materials, especially under osteoporotic conditions, there is 
a need for the development of effective and safer alternatives [3, 4]. One proposed 
strategy has been the addition of osteoinductive factors or osteoprogenitor cells to a 
bone substitute, in order to improve osteogenesis, particularly when impaired healing 
response is expected [5-7]. 
Strontium (Sr) is a trace element that simultaneously stimulates bone formation 
and inhibits bone resorption [8-10]. Nevertheless, the cardiovascular safety of oral Sr 
ranelate is still a matter of concern as a small but significant increase in non-fatal 
myocardial infarctions has been reported [11-13], leading to strict indications and 
restrictions for its use [11].  
Several pre-clinical studies, performed in both normal and osteoporotic animal 
models, were consistent with previous in vitro studies, showing the beneficial effect 
of Sr ranelate in increasing bone architecture and bone strength [14-16]. Accordingly, 
in order to enhance bone repair, Sr has recently been incorporated into different 
bone substitutes. This strategy aims to achieve a safer use of its osteoanabolic and 
anti-osteoclastic activity, as high concentrations are achieved locally, improving bone 
formation with less systemic impact. However, in vivo studies are scarce, and most 
reports do not present an adequate control group. Whether Sr-enriched materials are 
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effective and safe is still a matter of debate, and more information on local Sr use is 
needed, with uniform criteria.  
The aim of this study was to systematically review the in vivo effect of Sr in 
bone formation and/or remodelling, when incorporated into biomaterials.  
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Materials and Methods  
A systematic search was performed in Pubmed and Scopus, using as a search 
strategy a combination of “Strontium”, “Bone regeneration”, “osteogenesis” (and 
similar terms such as ("Bone Substitutes" or Bone) and “Biomaterials” (and 
equivalents such as "Biocompatible materials" or "materials Testing" or "Tissue 
Scaffolds" or "Biomimetic materials"). The search was limited by english language, 
human or other animal species (in Pubmed) and articles published after 1990 until 
July 2015. Additional papers were retrieved by non-systematic searches of relevant 
sources and screening of all retrieved article references (Fig. 1).  
Increased bone regeneration was defined based on increased bone formation 
and/or increased bone remodelling. Two comparison groups were previously defined, 
as an experimental group (E), which received a Sr-enriched biomaterial for 
evaluation of bone support or regeneration, and a control group (C) that received a 
similar Sr-free material. The groups had to differ only in Sr addition to the biomaterial 
in order to be included. Subgroups were also defined when specific conditions were 
present in both experimental and control groups (such as osteoporosis).  
The study was conducted in two phases (Fig. 1). In each phase, two 
independent reviewers (NN and DL) analysed the references and pooled according 
to predefined inclusion – A) studies with original data, B) on Sr doped materials, C) 
used for bone support or regeneration, D) performed in vivo – and exclusion criteria – 
E) articles without a control group only different from experimental on Sr addition to 
the biomaterial, F) on Sr usage only as a substitute on implant coating material, and 
G) if full-text not available (Fig. 1). In phase one, titles and abstracts were screened, 
and articles proceeded to the next phase upon inclusion of at least one reviewer. In 
phase two, full texts were assessed and disagreements were discussed between 
reviewers. When the full text was not available, authors were contacted and asked 
for a full-text copy. There was no article excluded due to unavailability of its full text.  
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Fig 1. Flow diagram showing the study screening process. 
 
Using an electronic form pre-developed by the authors, two investigators (NN 
and DL) performed data extraction. Qualitative results on the effect of Sr on bone 
regeneration were extracted independently of technique used for assessing Sr effect 
in each group. General results on implant effect were retrieved from individual 
papers, with data presented according to the amount of Sr in each biomaterial, time 
between material implantation and the analysis, and presence of concomitant 
conditions. The reported effect of Sr on bone formation, bone remodelling and its 
adverse effects were converted in a graphic summary table. Increased bone 
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formation was considered as higher reported bone formation, total bone volume or 
other similar reference. Enhanced bone remodelling was defined as advanced 
maturation stage, higher biomaterial degradation, and central versus peripheral bone 
formation or similar.  
When available, data on significance from each study were also gathered, with 
a statistically significant value defined as p<0.05. Data on gene or protein expression 
were collected upon availability.  
This systematic review was conducted based on Preferred reporting Items for 
Systematic reviews and meta-analyses (PRISMA) statement guidelines [17]. The 
PRISMA statement checklist is available as Supplementary material.  
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Results  
A total of 572 references were retrieved after a literature search in Pubmed 
(210 references), and in Scopus (362 references), downgraded to 272 records after 
the application of exclusion criteria, the removal of duplicates, and the addition of 
hand and reference searches. In the title and abstracts selection phase, 231 records 
were excluded, mainly in vitro studies and studies on Sr’s usage as a coating 
material, rather than as an implant for bone support or regeneration. In the full text 
selection phase, 41 papers were included. Four full texts were not available but were 
retrieved after contact with the authors. From these, 14 papers were excluded, 
mostly due to absence of control groups that received a Sr-free material, otherwise 
similar to the experimental material, and 27 articles were included in the final review 
(Fig. 1) [15, 16, 18-42].  
General article information is available in Table I and general results on implant 
effect on Supplementary Table I. Rat models were used in 17 studies, nine were in 
rabbits and one in humans. The population of included studies ranged from four to 72 
animals (Table I). Apart from two articles, the primary goal of the papers was to 
assess the effect of Sr-enriched materials in the models studied. The majority of 
bone defects were created in long bones, mainly in the femur (n = 18). Most of the 
defects were drilled and bilateral, with some studies using the same animal in the 
control and experimental groups. Three studies used segmental defects (Table I).  
The major concomitant condition studied in the animal models was 
osteoporosis; two studies included models with and without osteoporosis, and nine 
included only osteoporotic animals. One study was performed on animals with 
osteonecrosis. In the remaining ten studies, all animals were healthy (Table I). The 
single article concerning humans included subjects who underwent a craniotomy due 
to different neoplastic and vascular conditions.  
Time from implantation to analysis varied among the different studies, ranging 
from six days to 12 months. The studies used different materials. (Table I). Two sets 
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of studies used similar materials; eight on bioactive glass and five on hydroxyapatite 
(HA)/Calcium phosphate (CP) cements. Sr concentration in the E group ranged from 
0.1% to 22% (Supplementary Table I). All but three studies performed histologic 
and/or histomorphometric analysis. Radiological analysis such as micro-CT, PET 
scan, radiograph or scintigraphy were used in 12 papers for imaging (Table I). Gene 
analysis and immunohistochemistry were available in two [21, 31] and six [16, 31, 34, 
38, 40, 41] papers, respectively. Data on protein or gene expression are displayed in 
Figure 2.  
 
ID 
 
Animal n  Concomitant 
conditions 
Defect   Material  Analysis 
E C Type mm Location E C  
Banarjee [18] Sprague 
Dawley rats 
8 4 H Bilateral 
drilled 
3 Distal 
Femur 
ß-TCP-
MgO/SrO 
cylinders  
ß-TCP 
cylinders 
Hist 
Bose [19] Sprague 
Dawley rats 
4 4 H Bilateral 
drilled 
3 Distal   
Femur 
ß-TCP-
MgO/SrO 
cylinders 
ß-TCP 
cylinders 
Hist 
Boyd [20] Wistar rats 12 12 O/H Unilateral 
drilled 
1 Midshaft 
Femur 
Sr-Bioactive 
glass 
Bioactive 
glass 
Hist 
Cardemil [21] Sprague 
Dawley rats 
32 32 O/H Bilateral 
drilled 
2.3 Distal 
Femur 
Sr-CP granules HA 
granules 
Hist*; G 
Cheng [22] Sprague 
Dawley rats 
22 21 O Unilateral 
wedge 
4 Distal 
Femur 
Sr-CPC Xerogel 
particles Sr-Fe 
foam 
CPC 
Xerogel 
particles 
Fe foam 
PET 
Cheng [23] Sprague 
Dawley rats 
7 7 O Unilateral 
wedge 
4 Distal 
Femur 
Sr-CPC CPC PET 
Dagang [24] New Zealand 
White rabbits 
2 2 H Unilateral 
drilled 
2.2 Distal 
Femur 
Sr-HA cement HA 
cement 
Hist 
Gorustovich 
[25] 
Wistar rats 15 15 H Bilateral 
drilled 
1.5 Tibia Sr-Bioactive 
glass 
Bioactive 
glass 
Hist* 
Gu [26] New Zealand 
White rabbits 
12 12 H Unilateral 
segmental 
15 Radius Sr-CPP scaffold Sr-CPP 
scaffold 
Hist* 
Lin [29] Fisher rats 3 3 O Drilled (2 
defects) 
5 Calvarius Sr-Ca Silicate 
scaffold 
Ca Silicate 
scaffold 
Hist*; µ-
CT 
Mohan [30] New Zealand 
White rabbits 
6 6 H Unilateral 
segmental 
15 Midshaft 
Ulna 
Sr-CP cylinders HA 
cylinders 
Hist*; µ-
CT 
Thormann 
[16] 
Sprague 
Dawley rats 
15 15 O Unilateral 
wedge 
4 Distal 
Femur 
Sr-CPC CPC Hist*; G; 
Immuno 
Tian [31] New Zealand 
White rabbits 
24 24 H Unilateral 
segmental 
15 Radius Sr-CPP scaffold CPP 
scaffold 
Hist*; X-
ray; 
Immuno 
Wei [32] Wistar rats 6 6 O Bilateral 
drilled 
3 Distal 
Femur 
Sr Bioactive 
glass 
Bioactive 
glass 
Hist*; µ-
CT 
Xie [33] New Zealand 
white rabbits 
NI NI H Unilateral  15 Femur K/Sr-CPP 
scaffold 
CPP 
scaffold 
Hist*; 
Zhao [35] Sprague 
Dawley rats 
6 6 H Drilled (2 
defects) 
5 Calvarius Sr Bioactive 
glass 
Sr 
Bioactive 
glass 
Hist*; µ-
CT 
Zhang [34] Wistar rats NI NI O Bilateral 
drilled 
3 Distal 
Femur 
Sr Bioactive 
glass 
Bioactive 
glass 
Hist*; µ-
CT; G; 
Immuno 
Baier [15] Sprague 
Dawley rats  
30 30 O Unilateral 
drilled 
2 Distal 
Femur 
Sr-CPC CPC Hist* 
Izci [27] Humans 4 4 Other† Unilateral 
drilled 
15 Cranium Si-Sr-HA peg Si-HA peg µ-CT; 
Scintigra
phy 
Li [28] Wistar rats 20 20 H Bilateral 
drilled 
3 Proximal 
Tibia 
Sr-CaS paste CaS paste Hist*; µ-
CT; X-ray 
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ID 
 
Animal n  Concomitant 
conditions 
Defect   Material  Analysis 
E C Type mm Location E C  
           
Jebahi [36] Wistar rats 5 5 O Unilateral 
drilled 
3 Distal 
Femur 
Sr Bioactive 
glass 
Bioactive 
glass 
Hist* 
Jebahi [37] Wistar rats 5 5 O Unilateral 
drilled 
3 Distal 
Femur 
Sr Bioactive 
glass 
Bioactive 
glass 
Hist* 
Kang [38] Japanese 
White rabbits 
 
18 18 ON Unilateral 
drilled 
3 Proximal 
Femur 
Sr-CPP scaffold  
and MNCs 
CPP 
scaffold  
and MNCs 
Hist*; X-
ray; 
Immuno 
Tarafder [39] Sprague 
Dawley rats 
4 4 H Bilateral 
drilled 
3 Distal 
Femur 
ß-TCP-
MgO/SrO 
cylinders 
ß-TCP 
cylinders 
Hist* 
Tarafder [40] New Zealand 
White rabbits 
2 2 H Bilateral 
drilled 
5.5 Distal 
Femur 
ß-TCP-
MgO/SrO 
cylinders 
ß-TCP 
cylinders 
Hist*; 
Immuno 
Xie [41] New Zealand 
White rabbits 
9 9 H Unilateral 15 Femur 
Shaft 
K/Sr-CPP 
scaffold 
CPP Hist*; X-
ray; 
Immuno 
Zhang [42] New Zealand 
White rabbits 
6 6 H Unilateral 
drilled 
6 Distal 
Femur 
Sr-Borate 
Bioactive glass 
Borate 
Bioactive 
glass 
Hist* 
Table I. Description of the sample and methods of the studies included 
 
Results stated by each paper on the effect of the Sr-enriched biomaterial in 
bone formation and/or remodelling are displayed in Supplementary Table I. Although 
five studies reported analysis with multiple Sr concentrations, only in three did the 
authors gather information on the comparison between materials with different Sr 
content. In two studies, a significant superior overall effect was found with materials 
enriched with higher Sr concentration; the other study that looked at various 
concentrations found non-significant differences. Only one article reported the 
differential effect between healthy specimens and those with osteoporosis, finding an 
increased effect in osteoporotic animals (Supplementary Table I).  
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Fig. 2. Summary of study results on gene and protein expression. When different results from different 
study times were available, they were stated. 
 
A graphic analysis on the result of the effect of the studied biomaterial in bone 
formation and remodelling, along with a summary of adverse effects reported by 
each paper, is presented in Table II. Two articles studying bone formation reported a 
similar effect in the E and C groups; another one reported similar effects only in 
osteoporotic animals but an increased effect in healthy ones [20]. Baier et al [15] only 
found significant differences in the third month in both bone formation and 
remodelling. Cheng et al [22] studied three materials, with different compositions, but 
only one material, calcium phosphate cement (CPC), resulted in an increased effect 
on the experimental group. Apart from these, all other studies with analysis on bone 
formation found an increased effect of enriched material (Tables II and III). Of the 
Gene	Expression
Protein	Expression
IL-6	(at	day	28)
CR	(at	day	28)
TNF-α	
IL-6	(at	day	6)
Caspase	(at	day	28)
ALP
Col1a
OC
OPG
RANKL
CR	(at	day	6)
CatK
VEGFA
Col1a1
RUN-X2
RANK-L
OPG
Car2	
OCN
ALP
Col10
VEGF
RANKL
BMP2
OPG
OCN
CD31	
Col1
Col1a1
Similar IncreasedDecreased
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studies with reports on bone remodelling, four showed similar results in experimental 
and control, four found an increased effect in experimental only in late study phases, 
and 17 reported an increased effect in the experimental group in all studied times 
(Table III).  
 
Article Strontium content Time  Bone 
formation 
Bone 
remodelling 
Adverse 
reaction 
Inflammatory 
reaction 
Bose, 2011 [18] 1 wt% 4 wks Increased NI   
  8 wks Increased NI   
  12 wks NI Increased   
  16 wks NI Increased   
Tian, 2009 [31] 1 wt% 4 wks Increased * Similar L 1 No 
  12 wks Increased * Similar   
  16 wks Increased * Similar   
Xie, 2012 [33] 2 wt% 4 wks Increased Similar   
  8 wks Increased Similar   
  12 wks Increased Increased   
  Overall Increased Increased  L 1 No 
Dagang, 2008 
[24] 5/10 wt% 
4/8/12/24 
wks Similar Increased L 1 No 
Gorustovich, 
2010 [25] 6 wt% 30 days NI Similar L 1 No 
Gu, 2013 [26] 11.5 Ca/Sr MR 4 wks NI Increased L 1 No 
  8 wks NI Increased L 1 No 
  16 wks Increased Increased L 1 No 
  Overall Increased Increased   
Banarjee, 2010 
[18] 0.25/1 wt% 4/16 wks NI Increased   
Li, 2014 [28] 5/10 wt% 4 wks Increased Similar   
  8 wks Increased NI   
  12 wks Increased Increased   
Mohan, 2012 
[30] 1.67 (Ca+Sr)/P MR 4/12 wks Increased * Increased * L 1 No 
Zhao, 2015 [35] 10 wt% 8 wks Increased * Increased *   
Izci, 2013 [27] NI 3/6/12 mths Increased  Similar L 1 No 
Kang, 2015 [38] 11.5 Ca/Sr MR 4/8/12 wks Increased * Increased * L 1 No 
Tarafder, 2013 
[39] 1 wt% 4 wks Increased * Increased * 
S (Similar Mg and Sr excretion 
in urine) 
  8 wks Increased * Increased * 
  12 wks Increased * Increased 
  16 wks Similar NI 
Tarafder, 2014 
[40] 1 wt% 8/12 wks Increased * Increased *  
Xie, 2013 [41] 11.5 Ca/Sr MR 4 wks Similar Increased L 1 No 
  8 wks Increased Increased L 1 No 
  12 wks Increased Increased L 1 No 
Zhang, 2015 
[42] 9 mol% SrO 4/8 wks Increased * Increased * L 1 No 
In	vivo	and	clinical	application	of	strontium-enriched	biomaterials	for	bone	regeneration	
	 49 
Article Strontium content Time  Bone 
formation 
Bone 
remodelling 
Adverse 
reaction 
Inflammatory 
reaction 
Boyd, 2009 [20] 0.14 SrO Mol Fract 4 wks NI Similar L 1 No 
 0.28 SrO Mol Fract 4 wks Increased NI L 1 No 
   Similar NI   
Cardemil, 2013 
[21] NI 6 days Similar NI L 1 Yes 
  28 days Similar Increased *   
  6 days Similar NI   
  28 days Similar Increased *   
Wei, 2014 [32] 5 wt% 2 wks Similar Similar   
  4 wks Increased * NI   
  8 wks Increased * Increased   
Thormann, 
2013 [16] 0.123 Sr/Ca MR 6 wks Increased * Increased *   
Zhang, 2013 
[34] 2.5 wt% 2 wks Increased * Increased * 
S Increased * (Significant Sr 
increase in blood and urine 
samples) 
  4 wks Increased * Increased * 
  8 wks Increased * Increased/ 
Similar 
 5 wt% 2 wks Increased * Increased * 
  4 wks Increased * Increased * 
Baier, 2013 [15] NI 1 mth Similar Similar 
S (Similar spine and 
contralateral BMD)   3 mths Similar Similar 
  6 mths Increased* Increased * 
Lin, 2013 [29] 10 wt% 4 wks Increased * Increased *   
Cheng, 2014 
[22] CPC – 8.36 wt% 6 wks Increased NI   
 Xerogel – 20 wt%  Similar NI   
 Iron Foam – 22 wt%  Similar NI   
Cheng, 2014 
[23] 8.36 wt% 6 wks Increased NI   
Jebahi, 2012 
[36] 0.1% 60 days Increased Increased S (Similar blood cell counts and 
similar Ca and P blood levels)      
Jebahi, 2013 
[37] 0.1% 90 days Increased * Increased * L 1 No 
Table II. Summary of general results on bone formation and bone remodelling from individual studies. 
Results are presented according to the content of Sr used in the biomaterial and the average time from 
implantation to evaluation 
Shaded cells represent results from osteoporotic models. *Statistically significant difference between 
experimental and control wt%, weight percentage; MR, molar ratio; Mol Fract, Molar Fraction; d, days; 
w, weeks; m, months; NI, No Information; L, local; S, Systemic; CPC, Calcium Polyphosphate Cement; 
BMD, Bone mineral Density ↔ Similar in experimental and control  
 
No study found a decreased effect of Sr addition in bone formation and/or 
regeneration when compared with controls. Overall, two articles had no report on 
bone remodelling, and another two did not report on bone formation.  
Of the 17 articles with results on adverse effects of the implanted biomaterial, 
13 reported similar local secondary effects in experimental and control. From these, 
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12 found no inflammatory reaction and one showed increased inflammation in both 
experimental and control. One article reported increased systemic effects of Sr 
application, with significantly raised levels of this ion in urine and blood samples, and 
the other three articles found no differences in systemic effects of Sr application.  
 
 
Time 
(wks) 
Healthy Osteoporosis 
No of 
articles 
Bone formation Bone remodelling No of 
articles 
Bone formation Bone remodelling 
Increased* Similar† Increased* Similar† Increased* Similar† Increased* Similar† 
1 1 1 0 0 0 1 1 0 0 0 
2 0 0 0 0 0 2 1 1 1 1 
4 14 3 8 5 8 6 3 3 1 3 
6 0 0 0 0 0 3 2‡ 3‡ 0 1 
8 10 1 8 1 7 3 0 3 0 3 
12 10 1 8 2 7 2 1 1 1 1 
16 5 1 2 1 3 0 0 0 0 0 
24 2 1 1 1 1 1 0 1 0 1 
48 1 0 1 1 0 0 0 0 0 0 
Table III. Number of studies stating a specific result on bone formation and bone remodelling according 
to the time from implantation to evaluation. The single article on osteonecrosis was excluded from this 
analysis. †experimental versus control; *experimental versus control; ‡Cheng, 2014 [35] have different 
materials 
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Discussion  
This is the first systematic review that summarizes the in vivo effect in bone 
formation and remodelling of Sr-enriched biomaterials. Overall, Sr improves bone 
formation and remodelling, leading to a higher response when compared with similar 
Sr-free materials. Sr effect is present even in osteoporotic environments and some 
studies report greater effects in these models (Supplementary Table I). Our results 
are in agreement with other reviews on other enriching elements [43, 44] and with 
previous in vitro results on Sr [9, 45-50]. 
 
Bone formation and remodelling: timing, models and health status 
From the 25 articles with results on bone formation, 23 report some kind of 
improvement in the experimental group. Although not all state a benefit in all study 
points, we observed that the Sr effect appears mostly in the later stages of each 
study. In fact, a tendency to an increase in the number of studies reporting a stronger 
effect of Sr in bone formation in later study points is observed when analysing 
studies according to the time of evaluation, as seen in Table III. Conclusions from 
studies with earlier assessment points therefore may be premature to differentiate 
the bone reaction between experimental and control. This may explain why Cardemil 
et al [21] found no differences, since the study ended just four weeks after 
implantation. However, some authors reported a significant improvement in 
experimental even at weeks two and four. One can argue that response to Sr may be 
influenced by the amount of time that the bone is exposed to this component.  
Few studies report similar effects on bone formation in experimental and 
control, and for each study time the number of studies reporting increased effect in 
experimental versus control is at least similar to the number of studies stating equal 
effects. When considering bone remodelling, fewer results are available, and the 
number of studies reporting increased bone formation and remodelling in 
experimental is only superior after six weeks. These results on bone formation and 
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remodelling are valid, independent of the model’s health status. This confirms 
previous reports on Sr, as a stimulator of bone differentiation and osteogenesis [9, 
45-50]. However, the optimal conditions for its usage are yet to be determined, in 
order to maximize its beneficial effects. Moreover, no study showed decreased bone 
formation or remodelling in experimental, in any time period, for either healthy or 
diseased models. The presence of a beneficial effect of Sr even in osteoporotic 
models, may enhance its therapeutic value, since osteogenesis impairment is a 
major challenge in this condition [4]. 
 
Biomaterials  
We decided to consider Strontium Calcium Phosphate (SrCaPO4) and Sr-HA 
as similar materials, since SrCaPO4 results from incorporation of Sr into HA [40]. 
However, it is known that incorporation of Sr into HA may impact its solubility [21], 
which may partially explain why only articles using biomaterials with Sr-HA showed 
no improved effect in E. Although Mohan et al [30] found a significant improvement in 
E using HA as a base material, we cannot make any comparison with the two other 
articles using HA since different defect models were used.  
The rate of Sr release from the biomaterial was also identified as a possible 
factor impacting its activity, since osteoblast-like cells use the strontium released 
from the biomaterial to synthesize their mineralised extracellular matrix [51]. 
Thormann et al [16] showed higher Sr concentrations in zones of increased bone 
formation, supporting this finding. More studies on the relationship between Sr 
concentrations and bone formation are needed to clarify this theory.  
 
Sr content  
Our study also showed that even small amounts of Sr might be enough to have 
an impact on both bone formation and remodelling since some authors found 
significant differences with only 0.1% of this component [36, 37]. However, two of the 
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three authors who specifically compared different Sr percentages found an increased 
overall response with higher concentrations [23, 24], confirming previous in vitro 
reports [52]. The other author reported similar results between E and C [28]. All three 
authors agree that the optimum dose of Sr is yet to be discovered, since it can 
impact both the bone response and material properties [24, 28, 34].  
 
Gene expression  
The available information on Sr impact on gene expression can be seen in 
Figure 2. Broadly speaking, little variation was found but a decrease in the pro-
inflammatory cytokine Il-6, a stimulator of osteoclast recruitment and bone 
reabsorption, related to altered bone metabolism, may help to explain the Sr effect as 
a promoter of bone formation and remodelling [53]. The increase in genes and 
proteins involved in these processes, such as osteocalcin and bone morphogenetic 
protein supports our reported results of Sr’s bone forming effects [53]. 
 
Side effects  
As previously stated, Sr systemic side effects were responsible for a 
downgrading of its interest for the scientific community, and for a move to local 
application of this component [11-13]. Our review found only four studies on the 
systemic repercussion of local Sr application. While one study reported increased 
levels of Sr in both urine and blood samples [34], another showed similar urinary 
excretion of this element [39]. The other two studies found no difference between 
experimental and control groups [15, 36]. One study reported increased values of 
serum Sr, but no comparison with C was performed, and the authors state that the 
concentration was 100 times lower than that needed to produce systemic effects 
[15]. Nevertheless, the pathological effects of these findings are not well known and 
still a matter of debate for future studies. A total of 13 reported on local effects, but 
no differences were found from C, and only one study found an increased 
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inflammatory reaction, both in experimental and control. Also, the short follow-up of 
most included studies impacts the ability to trace reliable conclusions on the adverse 
long-term effect of Sr.  
 
Methodologies and limitations 
The methods of the included studies were highly variable. First, different animal 
models were used, and only nine studies presented the same animal species. This 
can impact the results since it is known that both bone architecture and the 
regeneration process are different among species, posing problems when it comes to 
comparisons between studies [54, 55]. Also, all studies in animals used small 
species, with known differences in bone macroscopic, microscopic and remodelling 
properties when compared with humans [55]. Although larger animals, like dog and 
sheep, present a more reliable model, they may pose more ethical, housing, handling 
and availability issues [54, 55]. These variations between species may, at least 
partially, explain the different responses to the biomaterial found in the included 
studies. Only one article studied the application of Sr-enriched biomaterials in 
humans [27]. Although achieving an increased effect of Sr, the constraints of study 
design impact our ability to draw reliable conclusions. Even in the same species, 
defects differ in size, type and location. All studies that created a segmental defect 
found an increased effect of Sr on both bone formation and remodelling independent 
of the study time. This did not happen with other types of defect. One may suppose 
that segmental defects, with a greater impact on bone macrostructure, may influence 
either bone response, with the possibility of stimulation of a quicker reaction, or the 
ability to retrieve reliable results in the early stages. Guidelines are not available 
regarding the appropriate defect needed for each case, and a recent study pointed 
out that differences in defect creation impact the bone response [54].  More accurate 
and homogeneous lines of conduct are essential for the future design of comparable 
and reproducible study models.  
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As stated before, time to healing evaluation is variable among studies. 
Previous reports stated that fracture consolidation with a neocortex consisting of 
woven and lamellar bone is usually completed in an average of five to six weeks. 
However, different models, and even different bone defects, can alter this timeline 
[56]. 
Different methods for evaluation of response were found. Qualitative 
measurements, such as histology or imaging techniques, are observer-dependent 
subjective analyses, introducing bias to the reported results [57]. This may explain 
why Dagang, Kewei and Yong [24] found no significant differences between E and C 
since this study performed only a histological analysis. Our review has other 
limitations. Only 27 studies were retrieved. From these, 20 presented numeric results 
from histological analysis, but a quantitative synthesis of data was not possible since 
only a few performed comparable measurements of bone formation and/or 
remodelling. These studies, along with those with only qualitative data, were included 
in the review, allowing a broad qualitative assessment of published studies but no 
meta-analysis was performed. The definition of bone formation and bone remodelling 
was subjective and different in each study. Two reviewers performed the selection of 
relevant results but the absence of strict definitions increases the risk of bias. Many 
studies, especially those with only qualitative data assessment, did not present the 
significance of the comparisons, increasing the subjectivity of their interpretation.  
Future studies must follow appropriate protocols, and guidelines on results 
assessment for each technique should be drafted. The application of Sr in larger 
animal models, with longer follow-up times, is needed, with an appropriate monitoring 
of long-term local and systemic side effects. More studies on the comparison 
between diseased and healthy models, and between different Sr concentrations, 
would be of great importance to better understand the potentiality of this element.  
In conclusion, Sr is an apparently safe and effective doping material for 
stimulating bone formation and remodelling. Its effect may be more pronounced and 
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variable over time according to the concentration applied. Additionally, its benefit in 
osteoporotic models raises the possibility of its therapeutic value. However, the 
plethora of methods, measurements and protocols found in individual studies 
impacts the ability to perform a reliable data synthesis and analysis on Sr effect. It is 
important to develop adequate models and follow consistent guidelines of research in 
future studies, in order to better define the therapeutic application of this element.  
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Article focus 
• Systematic review 
• Assess the in vivo effect of Sr-enriched biomaterials in bone formation and/or 
remodelling 
 
Key messages 
• Increased bone formation and/or remodelling in biomaterials enriched with Sr  
• Sr effect is impacted by time and concentration 
 
Strengths and Limitations 
• First systematic review of Sr-enriched biomaterials 
• Inclusion of studies with heterogeneous methods may impact comparability 
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Supplementary Material 
	
ID Strontium 
content 
Time  Results 
Bose [19] 1 wt% 4 wks Increased bone formation in E versus C 
  8 wks Increased bone formation in E versus C 
  12 wks Presence of bone remodelling in E versus no bone remodelling in C 
  16 wks Bone remodelling with compact interface bone-implant in E versus fibrous 
interface in C 
Tian [31] 1 wt% 4 wks Similar observation of new bone in the margins of the implant, with no new bone 
formation in the centre in E and C. Increased number of osteoblasts 
(measurement of active bone formation) and presence of woven type of new 
bone in E versus C 
  12 wks Increased newly formed bone in E versus C; Presence of active osteoblasts in E 
and numerous osteoblasts in C; Presence of degradation of the scaffold in E 
  16 wks Presence of new bone regenerated and penetrated through the interconnective 
pores in E versus no new bone and only fibrous tissue in the centre of the 
scaffolds and increased quantity and density of the defected area in C 
  Overall Significantly increased percentage of new bone volume in E; Similar 
degradability and degradation rate in E and C 
Radiograph: Illegible bone boundary with implant in E and C 
Xie [33] 2 wt% 4 wks Increased bone volume in E versus C; Clearly visible interfaces of all the 
scaffolds in E and C 
  8 wks Increased bone volume in E versus C; Presence of new bone formation in the 
centre and similar degradation in E and C 
  12 wks Increased bone volume in E versus C; Large new bone in the centre of scaffolds 
with trabecular structure encasing the scaffold in E versus new bone regenerated 
and penetrated through the interconnective pores to the margin in C 
  Overall Incorporation of Sr decreased significantly the number of osteoclasts; 
Dagang [24] 5 wt% 4/8/12/24 
wks 
Higher degradability and mature bone (measured by haversian canals) in E 
versus C; similar/no inflammation reaction, no fibrous membrane on the 
interface, slight surface absorption in E and C. No significant differences in newly 
formed bone. 
 10 wt%  Higher degradability, mature bone (measured by haversian canals) and surface 
absorption (obvious absorption pores) in E versus C; similar no inflammation 
reaction, no fibrous membrane on the interface in E and C. No significant 
differences in newly formed bone. Sr 10% versus Sr 5%: higher degradation and 
higher absorption pores  
Gorustovich 
[25] 
6 wt% 30 days Similar affinity index (direct contact area), no fibrous layer, no macrophage and 
no inflammatory cells in the interface in E and C; EDX analysis with similar bond 
to bone through a calcium-phosphorus interface in E and C 
Gu [26] 11.5 Ca/Sr MR  4 wks Newly formed bone within and surrounding all the scaffolds in E versus only 
around the scaffolds in C 
 8 wks Presence of woven bone in E 
  16 wks Similar repair of most of the defect in E and C; greater ratio of newly formed 
bone/residual materials in E versus C 
  Overall Superior osteogenic capacity in E; Scaffold/bone boundary became illegible in E 
Banarjee [18] 0.25/1 wt% 4 to 16 
wks 
Presence of new bone on the pre-existing cortical bone and on the implant in E 
versus only on the pre-existing cortical bone in C 
Li [28] 5 wt% 4 wks Immature bone trabeculae and cancellous bone in E versus original repair in the 
defect area in C. Radiograph: presence of reabsorption in experimental and 
control 
  8 wks Well organised mature bone trabeculae in E versus immature bone trabeculae in 
C 
  12 wks Complete cortical repair in E versus cortical bone tissue with many voids in C. 
Radiograph: implant was not noted radiographically and the cortex closed in E 
and C; Slower resorption rates and more compact bone repair in E versus C 
 10 wt% 4 wks Well differentiated bone trabeculae in E versus original repair in the defect area 
in C. Radiograph: Presence of reabsorption in E and C 
  8 wks Regeneration of incomplete cortical surface at the same level of the adjacent 
cortical plate in E versus immature bone trabeculae in C 
  12 wks Complete cortical repair in E versus cortical bone tissue with many voids in C. 
Radiograph: Implant was not noted radiographically and the cortex closed in E 
and C; Slower resorption rates and more compact bone repair in E versus C 
 Overall Overall Micro-CT new bone formation and sporadic trabecular bone in the marrow canal 
in E and C; Improved new cortex formation in E versus C; significantly higher 
BMD and bone volume (relation BV/TV) in E versus C 
Sr 10% versus 5%: Non-significant difference in BMD and bone volume (relation 
BV/TV) in E versus C 
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ID Strontium 
content 
Time  Results 
Mohan [30] 1.67 
(Ca+Sr)/P MR 
4 wks Significantly more newly formed bone in E versus C 
12 wks Significantly more newly formed bone and material degradation in E versus C. 
Increased prominence of mature lamellar bone in E versus C 
  Overall Micro-CT: Increased bone volume, fraction trabecular number, trabecular 
thickness and bone density in E versus C 
Zhao [35] 10 wt% 8 wks Significantly higher mineralisation levels and new bone area in E versus C; 
Significantly lower material residual area in E versus C 
Micro-CT: Significantly superior bone volume (relation BV/TV), BMD and 
significantly higher blood vessel area and blood vessel number in E versus C 
Izci [27] NI 3/6/12 
mths 
Scintigraphy: Superior osteoblastic activity in E versus C. Micro-CT: Osseo-
integration in E and C 
Kang [38] 11.5 Ca/Sr MR 4 wks Significantly more newly formed bone in E versus C 
  12 wks Significantly higher defect repair and newly formed bone in E versus C. 
Radiograph: significantly higher trapdoor cartilage and defect repair in E versus 
C 
Tarafder [39] 1 wt% 4 wks Significantly higher bone area fraction (total newly formed bone area/total area) 
and osteoid area fraction (osteoid area/total area) in E versus C 
  8 wks Significantly higher bone area fraction and osteoid area fraction in E versus C 
  12 wks Significantly higher bone area fraction in E versus C. Completely mineralised 
bone formation in E versus presence of osteoid in C 
  16wks Similar bone area fraction in E versus C 
Tarafder [40] 1 wt% 8 wks Osteoid-like new bone formation E versus no osteoid-like new bone formation in 
C; Significantly higher bone area fraction (total newly formed bone area/total 
area) and osteoid area fraction (osteoid area/total area) in E versus C 
  12wks Significantly higher bone area fraction in E versus C; Significantly higher 
haversian canal area (haversian canal area/total area) in E versus C 
Xie [41] 11.5 Ca/Sr MR 4 wks Similar newly formed bone in E versus C; Similar new bone formation in the 
margins with no new bone in the centre of the implant in E and C; Higher 
degradability in E versus C 
  8 wks Higher newly formed bone in E versus C; Sporadic new bone formation in the 
centre of the implant in E versus no new bone in the centre in C 
  12 wks Higher newly formed bone in E versus C; Similar close union between implant 
and host bone in E and C; Trabecular bone in the centre of the implant in E 
versus only on the margins in C 
Zhang [42] 9 mol% SrO 4/8 wks Significantly higher bone-implant contact index in E versus C; Significantly lower 
Tb.Pf (Trabecular Bone Pattern Factor) in E versus C. Micro-CT: Significantly 
higher bone volume (relation BV/TV) in E versus C 
Boyd [20] 0.14 SrO Mol 
Fract 
4 wks Mixed response of bone and fibrous tissue and no medullary inflammation in E 
and C 
 0.28 SrO Mol 
Fract 
4 wks Presence of direct bone formation and no medullary inflammation in E 
  Cortical healing in 3 of 6 of E and 2 of 6 of C; Similar bone marrow bone 
formation in E and C 
Cardemil [21] NI 6 days Presence of local inflammatory reaction, with more new blood vessels and 
similar osteogenesis in E versus C 
 28 days Non-significantly higher proportion of bone at the centre of the defect in C versus 
significantly higher proportion of bone at the periphery of the defect in E; 
Significantly greater decrease in percentage of granule area in E versus C; less 
easily distinguished bone-granule interface in E; Bone formation in E and C 
  6 days Idem 6d 
  28 days Significantly higher proportion of bone at the centre of the defect in C versus 
significantly higher proportion of bone at the periphery of the defect in E; 
Significantly greater decrease in percentage of granule area in E versus C; less 
easily distinguished bone-granule interface in E; Bone formation in E and C 
Osteoporotic versus non-osteoporotic in E: trend to higher total-bone 
percentage; Significantly higher percentage of bone at the periphery 
Wei [32] 5 wt% 2 wks Similar new bone formation, presence of bone regeneration and woven trabecula 
in E and C 
  4 wks Significantly more new bone in E versus C 
  8wks Significantly more new bone, and superior bone thickness in E versus C 
Overall Higher degradation rate and rate of new bone formed in E versus C 
Micro-CT: Increased bone volume fraction in E versus C 
Thormann [16] 0.123 Sr/Ca 
MR 
6 wks Statistically higher new bone formation in E (also increased fragmentation and 
osteoid formation) versus C; Significantly more bone formation at the bone-
biomaterial interface region in E versus C; Significantly higher TRAP-positive 
cells in E versus C 
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Zhang [34] 2.5 wt% 2 wks Similar percentage of bone regeneration in E and C;  
Micro-CT: Significantly superior bone volume (relation BV/TV), trabecular 
number and trabecular thickness and significantly inferior trabecular separation 
in E versus C 
  4 wks Significantly higher percentage of bone regeneration in E versus C; Presence of 
maturing trabecula forming lamellar bone with osteoclasts involving the bone 
remodelling in E versus dispersed or scattered newly formed bone in C. Micro-
CT: Significantly superior bone volume (relation BV/TV), trabecular number and 
trabecular thickness and significantly inferior trabecular separation in E versus C 
  8 wks Significantly higher percentage of bone regeneration in E versus C; Greater 
amount and thickness of trabecula, with plenty of osteocytes clearly visible in the 
mineralised bone matrix in E versus C 
Micro-CT: Significantly superior bone volume (relation BV/TV), and trabecular 
thickness, similar trabecular number and trabecular separation in E versus C 
 5 wt% 2 wks Similar percentage of bone regeneration in E and C 
Micro-CT: Significantly superior bone volume (relation BV/TV), trabecular 
number and trabecular thickness and significantly inferior trabecular separation 
in E versus C 
Sr 5% versus Sr 2.5%: Similar percentage of bone regeneration; Micro-CT: 
Significantly superior bone volume (relation BV/TV), trabecular number and 
trabecular thickness, and significantly inferior trabecular separation in E versus C 
  4 wks Significantly higher percentage of bone regeneration in E versus C. Micro-CT: 
Significantly superior bone volume (relation BV/TV), trabecular number and 
trabecular thickness, and significantly inferior trabecular separation in E versus C  
Sr 5% versus Sr 2.5%: Micro-CT: Significantly superior bone volume (relation 
BV/TV), trabecular number and trabecular thickness, and significantly inferior 
trabecular separation in E versus C 
  8 wks Significantly higher percentage of bone regeneration in E versus C. Micro-CT: 
Significantly superior bone volume (relation BV/TV), and trabecular thickness, 
similar trabecular number and significantly inferior trabecular separation in E 
versus C. Sr 5% versus Sr 2.5%: Significantly higher percentage of bone 
regeneration; Micro-CT: Significantly superior bone volume (relation BV/TV) and 
trabecular thickness, similar trabecular number and trabecular separation in E 
versus C 
Baier [15] NI 1 mth Similar circumferential contact index, ingrowth index, implant discontinuities and 
implant discontinuities containing newly formed bone in E and C 
  3 mths Significantly higher circumferential contact index, ingrowth index, implant 
discontinuities and implant discontinuities containing newly formed bone in E 
versus C 
  6 mths Non-significantly higher circumferential contact index in E versus C; Significantly 
higher ingrowth index, implant discontinuities and implant discontinuities 
containing newly formed bone in E versus C 
Lin [29] 10 wt% 4 wks Significantly higher mineralised tissue, newly formed bone and blood vessels in 
E versus C; Significantly lower remnant scaffold area in E versus C. Micro-CT: 
Increased newly formed bone area, significantly increased new bone mineral 
density, higher bone volume/total volume ratio and higher trabecular thickness in 
E versus C 
Cheng [22] CPC – 8.36 
wt% 
6 wks PET scan: Significant increase in bone formation in the biomaterial-bone 
interface in E versus C; Non-significant differences in defect region in E versus C 
Xerogel – 20 
wt% 
 PET scan: No significant differences in bone formation in E versus C 
 Iron Foam – 
22 wt% 
 PET scan: No significant differences in bone formation in E versus C 
Cheng [23] 8.36 wt% 6 wks PET scan: Increased bone formation in E versus C 
Jebahi [36] 0.1 wt% 60 days Similar presence of newly formed bone in E and C; Highly cellular layer, more 
advanced ossification and more bone regeneration in E versus sparser osteoid 
deposition in C 
Jebahi [37] 0.1 wt% 90 days Significantly superior bone volume (relation BV/TV), osteoblast number and 
Ob.S/BS in E versus C; Significantly lower Oc.S/BS and OV/BV in E versus C; 
Similar mineralising surface (MS/CS) in E and C; EDX analysis showed higher 
bioactivity in bone-implant surface E versus C 
Supplementary Table I. Studies showing individual results of Sr effect on bone formation and/or bone 
remodelling. Results are presented according to the content of Sr used in the biomaterial and the 
average time from implantation to evaluation. E, Experimental; C, Control; w, weeks; d, days; m, 
months; wt%, weight percentage; MR, Molar Ratio; Mol Fract, Molar Fraction; CT, Computed 
Tomography; PET, Positron-Emission Tomography; EDX, Energy-dispersive X-ray analysis; BMD, Bone 
Mineral Density; BV/TV, Bone Volume/Total Volume; Ob.S/BS, Osteoblast/Bone Surface; OV/BV, 
Osteoid/Bone Surface; Oc.S/BS, Osteoclast/Bone Surface; MS/CS, Mineralising Surface. When 
available, comparisons among study times or Sr doses are presented. Unless stated otherwise, results 
are from histology and/or histomorphometric analysis. Shaded cells represent results from osteoporotic 
models.  
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Section/topic  # Checklist item  Reported on page #  
TITLE    
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT    
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
1 
INTRODUCTION    
Rationale  3 Describe the rationale for the review in the context of what is already known.  1/2 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
2 
METHODS    
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
N/A 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
2/Figure 1 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched.  
2/Figure 1 
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
2/Figure 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
2/Figure 1 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
2/3 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) 
and any assumptions and simplifications made.  
2-4 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
N/A 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  2/5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
5 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
2 
RESULTS  
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally with a flow diagram.  
2/3/Figure 1 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
3/4 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
N/A 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence 
intervals, ideally with a forest plot.  
Table 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
N/A 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
Table 3 
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Supplementary Table ii. Prisma Statement Checklist. N/A: Non-Applicable. From: Moher D, Liberati A, 
Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097.	  
Section/topic  # Checklist item  Reported on page #  
DISCUSSION  
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, and 
policy makers).  
7/8 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level 
(e.g., incomplete retrieval of identified research, reporting bias).  
7/8 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
7-9 
FUNDING  
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply 
of data); role of funders for the systematic review.  
10 
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Abstract 
Current challenges in the development of scaffolds for bone regeneration include the 
engineering of materials that can withstand normal dynamic physiological mechanical 
stresses exerted on the bone and provide a matrix capable of supporting cell 
migration and tissue ingrowth. The objective of the present work was to develop and 
characterize a hybrid polymer-ceramic injectable system that consists of an alginate 
matrix cross-linked in situ in the presence of strontium (Sr), incorporating a ceramic 
reinforcement in the form of Sr-rich microspheres. The incorporation of Sr in the 
microspheres and in the vehicle relies on the growing evidence that Sr has beneficial 
effects in bone remodeling and in the treatment of osteopenic disorders and 
osteoporosis. Sr-rich porous hydroxyapatite microspheres with a uniform size and a 
mean diameter of 555 µm were prepared, and their compression strength and 
friability tested. A 3.5% (w/v) ultrapure sodium alginate solution was used as the 
vehicle and its in situ gelation was promoted by the addition of calcium (Ca) or Sr 
carbonate and Glucone-δ-lactone. Gelation times varied with temperature and cross-
linking agent, being slower for Sr than for Ca, but adequate for injection in both 
cases. Injectability was evaluated using a device employed in vertebroplasty surgical 
procedures, coupled to a texture analyser in compression mode. Compositions with 
35% w of microspheres presented the best compromise between injectability and 
compression strength of the system, the force required to extrude it being lower than 
100 N. Micro CT analysis revealed a homogeneous distribution of the microspheres 
inside the vehicle, and a mean inter-microspheres space of 220 µm. DMA results 
showed that elastic behavior of the hybrid is dominant over the viscous one and that 
the higher storage modulus was obtained for the 3.5%Alg-35%SrHAp-Sr formulation. 
 
Keywords: Biomaterials; injectable bone substitute; strontium; alginate; 
hydroxyapatite 
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Introduction 
Osteoporosis is a systemic disease that affects a significant part of the aging 
population in western countries. It results in progressive loss of mineralization and 
consequent changes in bone architecture leading to increased susceptibility to 
fractures. Because of the raise in expectancy of life, osteoporosis has become a 
serious public health issue that will probably be worsened in the near future. The 
treatment of bone defects in osteoporotic fractures remains a significant challenge. 
The use of calcium phosphate ceramics in bone regeneration, either alone or in 
combination with a polymeric phase, is now a common practice, since these 
materials provide good biological responses, based on their osteoconductive 
properties, and adequate mechanical properties [1-5]. The development of injectable 
materials for filling bone defects allows for the use of minimally invasive techniques. 
Most injectable ceramic materials consist of micro or nanoparticles suspended in 
appropriate vehicles [6-11]. Spherical particles are more suitable for implantation 
than non-homogeneous granules, since they conform better to irregular implant sites 
and present more predictable flowing properties during injection [12-15]. The space 
between particles is critical for the success of a scaffold for bone regeneration since 
blood vessels and cells should be able to invade the inter-particle network to promote 
bone formation throughout the filled defect. It is generally accepted that a size of 
100-200 µm in diameter is suitable for bone in-growth [16]. 
The addition of inductive factors or osteoprogenitor cells is a current strategy to 
improve osteogenesis in osteoporosis [17-20]. Sr is a trace element that plays a dual 
role in bone metabolism, stimulating bone formation and inhibiting bone resorption 
[21-26]. In vitro pre-clinical studies indicate that Sr decreases bone resorption by 
directly inhibiting the differentiation, resorbing activity and apoptosis of osteoclasts 
[21, 25-27]. It was also observed that it enhanced the replication of preosteoblastic 
cells and osteogenic differentiation, reduced osteoblasts apoptosis and, secondarily, 
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promoted bone matrix synthesis [21, 24, 26, 28, 29]. At least three mechanisms are 
involved in the opposite effects of Sr: activation of the calcium-sensing receptor 
(CaSR), nuclear factor of activated Tc (NFATc)/Wnt signaling, and modulation of 
osteoprotegerin (OPG) and receptor activator of nuclear factor κ-B ligand (RANKL) 
[21]. The available in vivo data are consistent with the in vitro studies showing the 
beneficial effect of Sr in increasing bone architecture and bone strength in both intact 
and osteoporotic animal models [22, 30-35]. Sr has been used in clinical practice 
against osteoporosis as oral Sr ranelate, and has shown effectiveness in the 
prevention of both vertebral and non-vertebral osteoporotic fractures [21, 36, 37]. 
Incorporating Sr in calcium phosphate cements may be a strategy to achieve high Sr 
concentrations not in a systemic but in a local environment, using the osteoanabolic 
and anti-osteoclastic activity for enhancement of new bone formation [38-40]. 
Our group has developed an injectable system based on hydroxyapatite 
microspheres and an alginate-based vehicle with gel-forming ability [41]. We have 
extensively studied various types of microspheres, namely of calcium alginate [42], 
hybrid calcium phosphate/alginate [43] and calcium phosphates [44, 45].  
In the present work we propose an injectable hybrid system that consists of a 
polymeric matrix cross-linked in situ with Sr, reinforced with Sr-rich calcium 
phosphate microspheres, to be used for bone regeneration. The reasoning behind 
this strategy is that our hybrid system will provide both a scaffold capable of 
supporting cell migration and tissue ingrowth and incorporate two Sr release kinetics, 
in order to guarantee an effective bone remodeling since the early stages of 
implantation. 
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Materials and Methods 
1. Microspheres preparation and characterization 
1.1. Microspheres preparation 
HAp-microspheres and Sr-HAp microspheres were prepared using the droplet 
extrusion method combined with ionotropic gelation in the presence of Ca2+ and Sr2+ 
respectively. A homogeneous paste, obtained by dispersing the ceramic powder 
(HAp, Plasma Biotal) in a 3% (w/v) sodium alginate solution, was extruded drop-wise 
into a CaCl2 or SrCl2 cross-linking solution with a concentration of 0.1 M, where 
spherical-shaped particles were instantaneously formed due to the rapid 
establishment of Ca or Sr mediated junctions between polyguluronate chains on the 
polymer backbone. 
Different ceramic-to-polymer solution ratios were tested, the 0.2 w/w being the one 
that resulted in more reproducible results. The size of the microspheres was 
controlled by regulating the extrusion flow rate using a syringe pump, and by 
applying a coaxial air stream (Encapsulation unit Var J1, Nisco Engineering AG). At 
completion of the gelation period the microspheres were recovered and rinsed in 
water. Finally, they were dried and sintered at 1100 ºC and 1200 ºC (Euroterm 2408 
MLE, Termolab).  
 
1.2. Microspheres characterization 
HAp and Sr-HAp microspheres were characterized in terms of diameter (laser beam 
diffraction - Coulter LS, Beckman Coulter), porosity (mercury porosimetry - AutoPore 
IV, Micromeritics) and specific surface area (gas adsorption according to the 
Brunauer, Emmel and Teller-BET method - ASAP 2000, Micromeritics). 
Morphological and physic-chemical characterization of the microspheres was carried 
out using scanning electron microscopy (SEM-EDS), X-ray diffraction (XRD) and 
Fourier transform infrared spectroscopy (FTIR). The SEM/EDS exam was performed 
using a high resolution (Schottky) Environmental Scanning Electron Microscope with 
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X-ray Microanalysis and Electron Backscattered Diffraction analysis: Quanta 400 
FEG ESEM/EDAX Genesis X4M. Samples were coated with an Au/Pd thin film, by 
sputtering, using the SPI Module Sputter Coater equipment. For FTIR and XRD 
analysis, microspheres were reduced to powder and analysed respectively as KBr 
pellets using a spectrophotometer (Spectrum 2000, Perkin Elmer) and as powder 
particles using a diffractometer (Philips X-Pert). Zeta potential of hydroxyapatite 
microspheres was determined from streaming potential measurements with a 
commercial electrokinetic analyser (EKA, Anton Paar GmbH) using a special 
cylindrical cell with a powder insert for granular or powder samples. The electrolyte 
used was 1 mM KCl and the pH was slowly changed from 3 to 10. Mechanical 
characterization of the microspheres (friability and rupture force) was performed 
using a friability tester and a texture analyser. Friability tests were implemented 
according to a procedure described in the European Pharmacopeia (7th edition) with 
minor modifications. Briefly, 2 g of microspheres were loaded into a drum (F1, Sotax 
AG,) operating at 25 rpm. The fall height was 150 mm and the same microspheres 
were used for three cycles of 4 min each. After each cycle, the desegregated powder 
was blown out and the microspheres were collected and weighted again [41]. 
Friability was reported as percentage of total weight lost. Microspheres rupture force 
(hardness) was evaluated in a texture analyser (TA-XT2i, Stable Micro Systems). 
The load was applied vertically to individual microspheres, using a load cell of 5 kg 
and a cylindrical metallic probe with a diameter of 2 mm at a displacement rate of 0.1 
mm/s. The rupture force was determined from the maximum force reached (breaking 
point). In each experiment, 10 microspheres were assayed and the mean value from 
at least three experiments was calculated. 
 
2. Vehicle characterization 
2.1. Alginate molecular weight determination 
An ultra-pure sodium alginate (NovaMatrix, FMC Biopolymers) with >60% content of 
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guluronic vs. mannuronic acid units was used in the experiments. The molecular 
weight of the alginate was calculated by gel permeation chromatography/size 
exclusion chromatography (GPC/SEC). The analysis was performed at room 
temperature (circa 23 ºC), using a modular system, composed by an isocratic pump, 
a vacuum degasser and an autosampler module (GPC Max, Viscotek), a 
viscometer/right angle laser light scattering (RALLS) and a dual detector (T60, 
Viscotek), and a refractive index detector (K-5002, Knaeur), operating at the same 
wavelength as the RALLS detector (670 nm). Separations were performed in a set of 
PL aquagel- OH mixed columns. The mobile phase consisted of 0.1M NaNO3 with 
0.02% w/v NaN3 and the flow-rate was maintained at 1.0 mL/min. Samples were 
dissolved in the mobile phase at 1 mg/mL, filtered, and 100 µL of sample were 
injected by the autosampler on an automatic injection valve equipped with a 200 µL 
loop. All modules were controlled and sample data analysed by the OmniSEC Triple 
Detection/Light Scattering GPC/SECModular GPCMax software. Samples were 
analyzed in quadruplicate.  
 
2.2. Gel formation 
Internal gelation of the Na alginate solution was promoted using a method previously 
described by Kuo and Ma [46] with minor modifications, described elsewhere [41]. 
Briefly, a Ca or Sr salt with limited solubility, in this case CaCO3 or SrCO3, was mixed 
with the alginate solution and used as a source of Ca or Sr ions respectively. The 
release of Ca or Sr into the solution was promoted by the generation of an acidic pH 
with Glucone-δ-lactone (GDL, Sigma), a slowly dissociating acid, which was also 
incorporated in the solution. Once released, Ca or Sr ions can participate in the 
interchain ionic binding between carboxyl groups (COO-) of guluronic acids blocks in 
the polymer chain, giving rise to a cross-linked gel. The CaCO3/GDL or SrCO3/GDL 
ratio was set at 0.5 to yield a neutral pH value. All components were pre-equilibrated 
at room temperature (set at 20 ºC) before being mixed. An aqueous CaCO3 or SrCO3 
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suspension previously mixed and vortexed for 1 min was added to the Na-alginate 
solution (3.5% w/v). A Ca2+/COO- or Sr2+/COO- ratio of 0.288 was used, since 
preliminary results showed that it promotes gelation in an adequate handling period, 
giving the surgeon enough time to prepare, manipulate, and inject the system. To 
initiate gel formation, a fresh GDL solution was vortexed for 20 s and subsequently 
added to each mixture. The curing time of alginate was studied using a rheometer 
(Kinexus Pro, Malvern Instruments), by monitoring the temporal evolution of storage 
modulus (G’) and loss modulus (G’’). The storage modulus is an indicator of the 
degree of elasticity of the material, and the loss modulus is a measure of the degree 
of viscous behavior. The crossover of G' and G'', is defined as the gel point, the point 
at which the material properties change from a more “liquid-like” to a more “solid-
like”. Parallel-plates measurement system was used, in shear-controlled oscillatory 
mode. The plate’s distance (working gap) was set to 0.5 mm; the shear-strain applied 
was 5% of the gap (according to the Linear Viscoelastic Region (LVR) of the alginate 
hydrogels), at a frequency of 1 Hz. The temperature was set to 37 ºC and 20 ºC, and 
the solvent pool was used to maintain the water-saturated environment and avoid 
any water evaporation from the alginate solution during the tests.  
 
3. Hybrid system preparation and characterization 
3.1 Hybrid system preparation 
For the hybrid system, alginate was combined with Ca or Sr microspheres and cross-
linked by internal gelation with Ca or Sr, respectively (hereafter designated as Ca- or 
Sr-hybrid). This formulation and methodology were adapted and optimized from 
previous works using ceramic microspheres and Ca-cross-linked alginate hydrogels 
[41, 43, 44, 47, 48]. Alginate was thoroughly mixed with an aqueous suspension of 
Ca carbonate (CaCO3, Fluka) or Sr carbonate (SrCO3, Sigma) at a CaCO3/COOH or 
SrCO3/COOH molar ratio of 1.6. A fresh solution of GDL was added to trigger gel 
formation. The CaCO3/GDL or SrCO3/GDL molar ratio was set at 0.125. The total 
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polymer concentration ranged from 3 to 4% w/v in deionized water. Microspheres 
were added to the alginate solution to yield different weight percentages ranging from 
10 to 35% w of the total solution and homogeneously suspended in the alginate 
solution (Fig. 1). 
 
Figure 1. Scheme of hybrid preparation: Alginate was mixed with an aqueous suspension of Ca or Sr 
carbonate. A fresh solution of GDL was added to trigger gel formation. Microspheres (10 to 35% w of 
the total solution) were added and homogeneously suspended in the alginate solution. 
 
3.2 Hybrid system characterization 
3.2.1 Injectability tests 
In the procedure, an injection device commonly used in vertebroplasty surgical 
procedures was used, which was coupled to a texture analyser [Fig. 2(A and B)]. The 
device consisted of a plastic syringe (20 mm internal diameter), a cannula (2.7 mm 
internal diameter, 173 mm length) and a polymeric connection tube. The syringe was 
filled with extemporaneously prepared microspheres-vehicle mixtures and the whole 
device was mounted on the texture analyser operating in the compression mode (TA-
XT2i, Stable Micro Systems). For extrusion, the load was applied vertically using a 
load cell of 30 kg and a plunger displacement rate of 1 mm/s for a distance of 35 
mm. Results were expressed as the force needed to extrude the mixture out from the 
syringe at room temperature. All samples were assayed at least in triplicate. 
 
3.2.2 Compression tests 
The microspheres-vehicle mixtures were extruded into cylindrical shape molds, 
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transferred to an oven at 37 ºC under controlled humidity (to prevent dehydration) 
and incubated for 24 h. At the end, cross-linked systems with a cylindrical shape 
were obtained. 
The compression strength of the systems obtained after 24 h of incubation was 
evaluated with a texture analyser (TA-XT2i, Stable Micro Systems), with the load 
applied vertically using a load cell of 30 kg and a disk shaped probe with a 50 mm 
diameter covering a distance of 5 mm at a displacement rate of 1 mm/s [Fig. 2(C)]. 
For each hybrid composition, compression tests were performed in a minimum of 3 
separate cylinders and the force profile curves were used to estimate the associated 
compression strength (maximum force). 
 
Figure 2. A – Injection device commonly used in vertebroplasty surgical procedures coupled to the 
texture analyser (A and B); Compression test of cylindrical shape sample (C). 
 
3.2.3 DMA tests 
The Dynamic Mechanical Analysis (DMA) supplies an oscillatory force, causing a 
sinusoidal stress to be applied to the sample, which generates a sinusoidal strain. In 
DMA, a complex modulus (E* = E´ + iE˝), an elastic modulus (E′) and an imaginary 
(loss) modulus (E″) are calculated from the material response to the sine wave. The 
E’ and E’’ gives information respectively, on the ability of the material to return and 
lose energy. The ratio of these two effects (Tan δ = E˝/E´) is called damping. 
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The DMA compression mode (DMA 8000, Perkin Elmer) was used to study the 
viscoelastic properties of the Ca and Sr vehicle (Alg-Ca and Alg-Sr, respectively) and 
of the hybrid system cross-linked with Ca and with Sr. Cylinders of 5 mm in diameter 
and 4 mm height were tested. The system comprises a parallel-plate measuring 
system to compress the specimen between the upper and lower platen. A frequency 
of oscillation of 1 Hz, and displacement amplitude of 1% of the thickness were used 
throughout the experiments. The influence of cross-linking agent of the vehicle, 
sintering temperature, percentage of microspheres, and time of curing were 
investigated. All the measurements were carried out at controlled temperature (20 
ºC), to prevent the dehydration of the samples. Five specimens were tested for each 
condition.  
 
3.2.4 Evaluation of the space between particles using micro-CT 
The spatial distribution and size of the interstices between the microspheres was 
evaluated from high-resolution 3D micro-computed tomography (µCT) data sets. 
Micro-CT analysis was performed on a hybrid system cylinder composed of 3.5%Alg-
35%Sr-HAp cross-linked with Sr. Briefly, a cylinder (3x4 mm) prepared in the same 
conditions described in sections 3.1 and 3.2.2. was incubated for 24h at 37 ºC under 
controlled humidity, and sequentially analyzed, using a high-resolution µCT Skyscan 
1072 scanner (Skyscan, Kontich, Belgium). The sample was scanned in high 
resolution mode, using a pixel size of 8.79 µm and an integration time of 1.7 ms. The 
X-ray source was set at 75 keV of energy and 132 µA of current. A 1 mm-thick 
aluminium filter and a beam hardening correction algorithm were employed to 
minimize beam-hardening artifacts (Skyscan hardware/software).  
Representative datasets of 373 slices were used for morphometric analysis. Binary 
images were created using two different thresholds, 50-255 and 150-255. 
Additionally, 3D virtual models were created, visualized, and registered using image 
processing software (ANT 3D Creator v2.4, Skyscan). Fully automated computer 
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algorithms were implemented for segmentation and analysis, using ITK and VTK 
toolkits. 
 
3.2.5 Statistical analysis 
Microspheres diameter, rupture force and molecular weight were reported as 
mean±standard deviation. Normality tests were performed with Shapiro-Wilk test in 
order to assure normal distribution of the data obtained. The equality of variances 
assumption was verified with the Levene's test. The effect of the microspheres 
composition on rupture force was statistically evaluated by Student´s t-test. The 
effect of different composition of vehicle and microspheres on the extrusion force and 
on compression strength was statistically evaluated by one-way ANOVA. Post hoc 
comparisons of the means of individual groups were performed using Tukey’s 
Honestly Significant Difference test. A value of p<0.05 was taken to denote 
significance. Statistical analysis was performed with IBM SPSS Statistics for 
Windows, Version 22.0 (Armonk, NY, IBM Corp, USA). 
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Results 
1. Microspheres characterization 
Microspheres with mean final diameters of 553±1.97 µm and 556±3.91 µm were 
obtained for the Sr-HAp and HAp formulations, respectively. Mercury porosimetry 
results indicated that both microspheres formulations present similar porosity 
percentage (29%) the median pore diameter for the Sr-HAp microspheres being 
higher (0.58 µm) than the one observed for the HAp microspheres (0.28 µm). 
Surface area measurements indicated a specific surface area of 2.860 m2g-1 for Sr-
HAp microspheres and 3.647 m2g-1 for the HAp microspheres. Scanning electron 
microscopy revealed that in both cases microspheres were uniform in size and shape 
(Fig. 3). At high magnifications, non-sintered microspheres presented a 
homogeneous distribution of the ceramic phase in the alginate matrix. Upon sintering 
the polymer phase was substituted by a porous network.  
 
Figure 3. SEM images of Sr-HAp porous microspheres, with increasing magnification revealing the 
microstructure of the particles. 
 
The isoelectric point of HAp microspheres occurred at approximately pH 4.5 whereas 
the isoelectric point of Sr-HAp microspheres occurred at approximately pH 4. At 
physiological pH both microspheres were negatively charged, the potential of Sr-HAp 
microspheres being more negative than that of HAp microspheres. Subtle spectral 
changes in the PO43- domains were observed in the FTIR spectra of the Sr-HAp 
microspheres suggesting the incorporation of Sr in the HAp lattice. In what concerns 
XRD results, after sintering no extraneous phases were observed in HAp and Sr-HAp 
microspheres. EDS analysis showed that approximately 4.0% w (1.2% At) of Sr was 
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incorporated in the Sr-HAp microspheres. Significantly different rupture forces of 
1.1±0.3 N and 0.5±0.2 N were observed for the Sr-HAp and HAp microspheres, 
respectively, sintered at 1200 ºC (p<0.001). Lower values were obtained for the 
particles sintered at 1100 ºC. Friability <0.1% was observed for the Sr-HAp and for 
the HAp microspheres. 
 
2. Vehicle characterization 
A molecular weight of 131±13 kDa was obtained for the ultrapure alginate used 
throughout the experiments.  
The gel point occurred at a time of approximately 7 min for the Sr vehicle and 25 min 
for the Ca vehicle at 37ºC, and 20 min for the Sr vehicle and 45 min for the Ca 
vehicle at 22 ºC (normal temperature of an operating room) (Fig. 4). 
 
Figure 4. Mean gelation times for 3.5%Alg-Ca and 3.5%Alg-Sr 3.5% gels at 37 ºC and 22 ºC (error bars 
represent the standard deviation - sd). 
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3. Hybrid system characterization 
3.1 Injectability and compression tests 
Using an extrusion rate of 1 mm/s, the maximum force required to extrude the hybrid 
systems with a composition of 3%Alg-25%HAp and 3%Alg-30%HAp (vehicle cross-
linked with Ca) was well below the 100 N, limit commonly referred for manual 
procedures [49]. Increasing the percentage of microspheres to 35% w, led to an 
increase of the extrusion force needed, exceeding the 100 N limit.  
When Sr was the reticulation agent of the alginate and Sr-HAp microspheres were 
used, the extrusion force needed was smaller, not exceeding the 100 N limit. 
When increasing the alginate concentration of the vehicle from 3 to 3.5% w/v and 
using Sr as the cross-linking agent, there was an increase in the extrusion force 
although not exceeding the 100 N limit (Fig. 5 A, 6 A). Keeping the same 
concentration of alginate but varying the type of microspheres (Sr-HAp instead of 
HAp microspheres) a higher force was needed to extrude the hybrid system. 
Although no statistically significant differences were observed for the compression 
strength values of the various formulations tested, the maximum mean value (42.6 N) 
was obtained with 3.5%Alg-35%Sr-HAp-Sr composition (Fig. 5 B, 6 B). 
 
Figure 5. A) Boxplot representing the extrusion force needed for the hybrid compositions of 3.5%Alg-
35%Sr-HAp cross-linked with Sr, 3%Alg-30%HAp cross-linked with Ca and 3%Alg-30%Sr-HAp cross-
linked with Ca in the extrusion test. B) Boxplot representing the force needed for the hybrid 
compositions of 3.5%Alg-35%Sr-HAp cross-linked with Sr, 3%Alg-30%HAp cross-linked with Ca and 
3%Alg-30%Sr-HAp cross-linked with Ca in the compression test. 
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Figure 6. Typical stress-strain curves for injectability (A) and compression tests (B) for the hybrid 
composition of 3.5%Alg-35%Sr-HAp cross-linked with Sr. 
 
3.2 DMA tests 
When comparing the vehicle of alginate cross-linked with Ca with the one cross-
linked with Sr, it was observed a higher storage modulus for the former (Fig. 7). 
 
 
Figure 7. Mean values of storage (E’), loss modulus (E’’), and tan δ for alginate cross-linked with Ca 
(Alg-Ca) and with Sr (Alg-Sr) (error bars represent the standard deviation). 
 
The addition of microspheres to the polymer increased the storage modulus, the 
increase being proportional to the percentage of microspheres. This is expected 
because HAp-microspheres are much stiffer than alginate. 
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The tan δ increased proportionally to the increase of microspheres percentage due to 
the increase of loss modulus as a consequence of particles friction (Fig. 8). 
 
Figure 8. Storage (E’), loss modulus (E’’), and tan δ for Sr-hybrid with different microspheres 
percentages. 
 
It was also observed that the sintering temperature of the microspheres influenced 
the storage modulus of the hybrid. A sintering temperature of 1200 ºC led to 
microspheres with higher compression strength, and consequently higher hybrid 
stiffness. 
The influence of time of curing in the mechanical properties of the Sr-HAp hybrid was 
evaluated. The count up of the time began with the addition of GDL to the alginate 
solution. The results showed an increase of storage modulus till a time of 24 hours, a 
consequence of the increasing of cross-linking chains within the alginate, due to the 
presence of the Sr cation.  
In order to increase the compression strength of the hybrid, different vehicle and 
hybrid preparations were investigated (Fig. 9). 
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Figure 9. DMA tests of hybrid systems with different formulations (non confined). In the hybrid 
preparation microspheres sintered at 1200 ºC were used. 
 
The vehicles 3.5%Alg-Ca and 3.5%Alg-Sr were the ones that presented better 
mechanical properties without limiting the injectability. An increase of alginate and/or 
microspheres percentage led to better mechanical properties. The possibility of 
existing a synergistic effect between Ca and Sr, in the cross-linking process of the 
alginate, was also investigated (1:1 ratio). Results showed that this effect did not 
seem to occur, being the cross-linking with Sr alone more effective from a 
mechanical point of view. 
When used in bone defects, surrounded by bone which has a higher Young’s 
modulus, mechanical properties of this viscoelastic material may be altered, so 
dynamic tests were also conducted in confined conditions, in order to better simulate 
what happened when the hybrid is used as a reinforcement material. The hybrid was 
kept in a fixed stainless steel cylindrical mold that was positioned in a way that the 
driveshaft of the instrument did not touch the mold and was only in contact with the 
hybrid material. In confined conditions the storage modulus increased significantly, 
over sixteen folds.  
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3.3 Evaluation of the space between particles using micro-CT 
Figure 10 shows a reconstructed µCT image of a hybrid cylinder.  
The µCT quantitative analysis of the Sr-hybrid materials showed that 49.4% of the 
total cylinder volume is occupied by microspheres, with mean interparticle space of 
220.7 µm. It was also observed the presence of denser particles distributed between 
the microspheres in a percentage of 0.3%, possibly corresponding to non-dissolved 
Sr-carbonate. 
 
 
Figure 10. Micro-CT reconstructed image of Sr-hybrid system. Sr-HAp microspheres are represented in 
green.  Denser particles are represented in red, possibly corresponding to non-dissolved Sr-carbonate. 
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Discussion 
A wide variety of particle based fillers for bone regeneration has been described in 
the literature, including multifaceted granules and smooth spherical particles of 
various sizes, with or without pores, and with broad or uniform size distributions [3, 5, 
6, 16]. The size and shape of the particles dictate their spatial rearrangement within 
the implant site, playing a critical role in new bone formation. Particles diameter and 
shape are also relevant parameters when considering injection procedures, since 
uniform, spherical particles have more predictable flowing properties [12-15]. The 
microspheres prepared according to the methodology herein described, were 
uniform, both in terms of size and shape with mean diameters around 555 µm, an 
appropriate value for effective bone substitution [50]. Adequate mechanical 
properties of the microspheres are essential so they can resist damage during 
transportation, packing, handling, and injection. Friability of both microspheres 
composition (HAp and Sr-HAp) was below detectable levels, and rupture force was 
adequate to withstand the pressure exerted during extrusion. The addition of Sr also 
doubles the rupture force of the microspheres. The reason for this can be related to a 
possible incorporation of Sr into the hydroxyapatite lattice by replacing Ca ions, as 
supported by FTIR results. It is well known that a wide range of cations and anions, 
may substitute into the structure of synthetic hydroxyapatite, replacing calcium, 
phosphate or hydroxyl ions. Ca2+ can be substituted to some extent by divalent 
cations, namely Sr2+. The substitutions alter the crystal lattice, inducing a structural 
disorder, and consequently changing some of the material properties, including 
phase stability, solubility, reactivity and mechanical properties. The ionic radius of Ca 
is about 0.99 Å, while the ionic radius of Sr is higher (1.13 Å). The incorporation of 
ions larger than Ca into the lattice of hydroxyapatite whereby an elongation of the 
lattice parameters and, as a result, a deformation of the elementary crystalline cell 
occurs. Chen et al. observed that the incorporation of low doses of Sr (atom ratio of 
Sr/(Sr+Ca) adjusted to 5%) improved the mechanical properties of hydroxyapatite, 
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namely compressive strength, Knoop hardness and indirect tensile strength [51].  
Alginate is a biomaterial that has found numerous applications in the biomedical field 
due to its favorable properties such as biocompatibility, ease of gelation and 
retention of structural similarity to the extracellular matrices in tissues [52]. Alginate is 
a natural linear polysaccharide that contains 1,4-linked beta-D-mannuronic (M) and 
alfa-L-guluronic (G) acid residues, arranged in a non-regular and block-wise fashion 
along the chain. Alginate is well known for its high affinity towards Ca [53]. Ca binds 
consecutive G-residues (G-blocks) in different alginate chains in a cooperative 
manner (egg-box model) producing the cross-links of the hydrogel. The cross-linking 
affects the resulting gel properties, such as stiffness, elasticity, and stability. Hence, 
the functional properties of alginate gels can be tailored by the selection of alginate 
composition. In general, alginate having a relatively high content of G (high-G 
proportion alginates) gives stiff and stable gels with a high porosity, whereas alginate 
with a low content of G (low-G or high-M proportion alginates) results in more elastic 
and less stable Ca gels. Having in mind the envisaged application, in the present 
work alginate with a content of more than 60% of guluronic vs mannuronic acid units 
was used. 
Alginate can also be cross-linked with other divalent ions, including Sr. Strontium 
ions have very high affinities towards alginate, and have been shown to bind to G- 
and M- blocks in the alginate [54].  
Ca and Sr-alginate gels can be made by internal gelation, meaning that the 
reticulation agents (Ca or Sr) are leaking at a low rate from an ion provider source 
within the alginate. In the present work, Ca and Sr were used in the form of 
carbonate and the release of the metal ions was caused by a reduction in pH due to 
the addition of GDL. The gelation process is highly dependent upon diffusion of 
gelation ions into the polymer network. An appropriate gelation time of the hybrid 
material will be important in clinical practice. It should not be too short so there is 
enough time to prepare and deliver the system, but not too long, to avoid an 
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excessively long surgical procedure. The gelation time for the Sr vehicle was 
significantly shorter than that of the Ca vehicle, but adequate (20 min.), at a normal 
operating room temperature. 
Alginate has been reported to be biocompatible and is, therefore, a good candidate 
for biomedical applications [47, 52]. Degradation of alginate is slow but can be tuned 
by manipulating polymer molecular weights and composition [55]. In order to promote 
bone regeneration, the injectable system that we propose should provide a scaffold 
capable of supporting cell migration and tissue ingrowth. One well-known strategy to 
promote cellular infiltration within a cell-free material and to direct de novo bone 
formation at the local implant site is the incorporation of guidance cues such as bio-
adhesive motifs derived from extracellular matrices into the biomimetic material [56]. 
Here, the implanted material provides not only the mechanical support for tissue 
regeneration but also appropriate guidance signals recognized by protein and 
proteoglycan receptors on cell surfaces. Grafting of RGD peptides on alginate is 
pertinent for the application envisaged in this work, since cell attachment is impaired 
on unmodified alginate. Although in the present work, hybrid system was based on 
non-functionalized alginate, tests were also performed using RGD functionalized 
alginate. No significant differences were observed in what concerns to the viscosity 
of the alginate and the injectability and mechanical properties of the complete 
system. 
The percentage and composition of microspheres, the alginate concentration and the 
reticulating agent influence the maximum force needed to perform manual injections, 
which should not exceed 100 N [49]. In a hybrid system of 3% alginate cross-linked 
with Ca, an increase of the percentage of microspheres to 35% increased the force 
needed for extrusion above the 100 N limit, and a filtering effect was observed, as 
the alginate extrudes quicker than the microspheres. Using Sr instead, as the 
reticulating agent, the extrusion force was smaller, allowing for an increase both in 
alginate concentration and percentage of microspheres. With the 3.5%Alg-35%Sr-
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HAp-Sr composition we obtained the higher compression strength value, still with an 
extrusion force below the 100 N limit. 
Also, the reticulation time when using Sr was smaller than when using Ca, as well as 
the respective modulus obtained in DMA tests. This is in accordance with the 
observation of Koo and Ma that alginate hydrogels formed with slower rates of 
gelation tend to exhibit greater structural homogeneity and therefore larger modulus 
than those gelled rapidly [46]. 
The viscoelastic properties of a bone defect filing material determine the capacity of 
dissipation of energy by bone, and influence the relative response of surrounding 
damaged and healthy tissue. DMA showed that for all tested materials E’ is higher 
than E” which indicated that the elastic behavior of the hybrid is dominant over the 
viscous one. Results also showed that the storage modulus was proportional to the 
HAp microspheres content as indicated in Fig. 7. The obtained results confirmed that 
the HAp particles acted as reinforcement filler by transferring the sustaining load 
from the matrix to the rigid particles.  
Although important features for bone repair, the mechanical properties of 
hydrogel/calcium phosphate composites have rarely been reported [57]. Current 
injectable bone defect fillers, like polymethylmetacrylate (PMMA) or calcium 
phosphate cements, have maximum compression strength values, which are much 
higher than that of cancellous bone. Besides, brittleness has limited the use of 
calcium phosphate cements [58, 59]. The elastic modulus of this hybrid system is 
below that of cancellous bone (20-5000 MPa) [60, 61], but when tested in a confined 
setting (as would be the case in bone defects) the elastic mode increases 
significantly. Low mechanical properties and the non-applicability in load-bearing 
situations are commonly cited limitations of hydrogels in bone tissue engineering 
[57]. However they can be used in non load-bearing sites, and, if necessary, 
supplementary internal fixation devices may be applied [62]. Small size defects (up to 
5-10 ml), where mechanical properties are not as critical, may be more adequate for 
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the use of this hybrid system.  
Besides the phase composition, numerous parameters influence bone regeneration. 
The internal structure of the particles, such as the porosity, the pore size distribution, 
or the size distribution of the pore interconnections, is of particular relevance. It is 
expected that the hybrid system that we propose will provide adequate mechanical 
support in the early phases after surgery and gradual replacement of the artificial 
scaffold by bone with adequate strength. The system, however, relies on the 
maintenance of part of its constituents (the microspheres), taking into account that 
full replacement by healthy, strong bone is not expected due to the age of the 
patients. Alginate is inherently non-degradable in mammals, as they lack the enzyme 
(i.e., alginase), which can cleave the polymer chains, but ionically cross-linked 
alginate gels can be dissolved by release of the divalent ions cross-linking the gel 
into the surrounding media due to exchange reactions with monovalent cations such 
as sodium ions. In the model that we propose, it is expected an adequate 
degradation behavior of alginate leaving a space between particles (220.7 µm) 
adequate for the invasion of blood vessels and cells. 
One advantage of the hybrid system developed in this project was the presence of Sr 
in its composition. Strontium, in the form of oral strontium ranelate, has been in 
clinical use as an anti-osteoporotic agent effective in the prevention of both vertebral 
and non-vertebral osteoporotic fractures [36, 37]. However, cardiovascular safety has 
been a concern regarding its use. Recently, a small but significant increase in non-
fatal myocardial infarctions was observed when analyzing all studies reporting the 
effect of strontium ranelate in osteoporosis and osteoarthritis [63-65]. Currently, the 
drug is authorized for the treatment of severe osteoporosis, in postmenopausal 
women and in adult men, at high risk of fracture for whom treatment with other 
medicinal products approved for the treatment of osteoporosis is not possible, and 
the use of strontium ranelate should be restricted to patients with no past or current 
history of ischemic heart disease, peripheral arterial disease and/or cerebrovascular 
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disease or uncontrolled hypertension. 
The incorporation of Sr in both the microspheres and the vehicle, will allow Sr 
release since the early stages of implantation, due to the different degradation 
kinetics of the polymer network (faster) and the ceramic particles (slower). It will be 
released locally to enhance bone formation, but clinically relevant systemic 
concentrations are not expected [38, 39, 66]. Baier et al. [39] compared the 
osteointegration of calcium phosphate cement implants containing Sr to calcium 
phosphate cement implants in ovariectomized rats, and found faster osteointegration 
and more new bone formation with the addition of Sr, both on the implant surface 
and within the implant. Systemic release of Sr from the implants did not induce 
significant effects on bone density in this rat model. Thormann et al. [38] studied the 
effect of Sr modified calcium phosphate cement (SrCPC) in bone formation in critical-
size metaphyseal fracture defects in ovariectomized rats. Both higher new bone 
formation in the SrCPC group compared to CPC group, and high Sr concentration in 
the interface region of the SrCPC implant were observed. They concluded that Sr 
release had most probably been responsible for these results, that local delivery of 
Sr from Sr-loaded biomaterials is possible, and that strontium’s biological activity to 
stimulate new bone formation is preserved within the CPC. 
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Conclusions 
We have developed a strontium rich viscoelastic hybrid system, herein described, 
that can be manually injected and sets in situ at body temperature, providing a 
scaffold for cell migration and tissue ingrowth. When implanted, the hybrid system 
will offer structural support while providing a temporary scaffold onto which new bone 
can grow. The incorporation of two Sr release kinetics (from the alginate and from 
the microspheres), may further improve effective bone regeneration, which can be 
especially useful in osteoporotic conditions. 
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Highlights 
• We developed a Sr rich viscoelastic hybrid system (alginate matrix cross-
linked in situ with Sr, and Sr-rich microspheres)  
• It can be manually injected, sets in situ and offers structural support, 
providing a temporary scaffold for bone growth 
• The incorporation of Sr relies on the growing evidence of its beneficial effects 
in bone remodeling and in osteoporosis 
• Two Sr release kinetics may further improve effective bone regeneration, 
which can be especially useful in osteoporosis 
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Statement of Significance 
Current challenges in the development of scaffolds for bone regeneration include the 
engineering of materials that can withstand physiological mechanical stresses and 
provide a matrix capable of supporting cell migration and tissue ingrowth. We have 
developed a strontium (Sr) rich viscoelastic hybrid system (alginate matrix cross-
linked in situ in the presence of Sr, and Sr-rich microspheres) that can be manually 
injected and sets in situ, offering structural support while providing a temporary 
scaffold onto which new bone can grow. The incorporation of Sr relies on the growing 
evidence of its beneficial effects in bone remodeling and in the treatment of 
osteoporosis. The two Sr release kinetics may further improve effective bone 
regeneration, which can be especially useful in osteoporotic conditions. 
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Graphical Abstract 
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Abstract  
Strontium (Sr) has been described as having beneficial influence in bone strength 
and architecture. However, negative systemic effects have been reported on oral 
administration of Sr ranelate, leading to strict restrictions in clinical application. We 
hypothesized that local delivery of Sr improves osteogenesis without eliciting 
detrimental side effects. Therefore, the in vivo response to an injectable Sr-hybrid 
system composed of RGD-alginate hydrogel cross-linked in situ with Sr and 
reinforced with Sr-doped hydroxyapatite microspheres, was investigated. The system 
was injected in a critical-size bone defect model and compared to a similar Sr-free 
material. Micro-CT results show a trend towards higher new bone formed in Sr-hybrid 
group and major histological differences were observed between groups. Higher cell 
invasion was detected at the center of the defect of Sr-hybrid group after 15 days 
with earlier bone formation. Higher material degradation with increase of collagen 
fibers and bone formation in the center of the defect after 60 days was observed as 
opposed to bone formation restricted to the periphery of the defect in the control. 
These histological findings support the evidence of an improved response with the Sr 
enriched material. Importantly, no alterations were observed in the Sr levels in 
systemic organs or serum.  
 
Keywords: strontium, bone regeneration, injectable bone substitute, alginate, 
hydroxyapatite, ionic delivery system 
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Introduction 
The management of fractures and bone defects remains a significant challenge, and 
there is the need for improved therapeutic strategies [1]. Biological (autografts, 
allografts and xenografts) and synthetic bone grafts are currently used in clinical 
practice for bone repair. Because of their osteogenic potential and the absence of 
risks of immune rejection or disease transfer, autografts are clinically preferred. 
However, they are limited in supply, imply the additional morbidity of a harvest 
surgery and their properties and shape do not match exactly those of the bone to be 
replaced [2]. Intensive investigation is being carried out to produce synthetic bone 
grafts in order to overcome these problems. The use of injectable materials in bone 
regeneration, especially calcium phosphate based materials, presents several 
advantages, namely due to their adequate biological responses, osteoconductivity 
and mechanical properties [3-6]. These materials can be applied by minimally 
invasive surgical procedures, to efficiently fill-in cavities of non-uniform shapes, with 
no tissue damage and limited exposure to infectious agents, thus reducing patient 
discomfort and procedure-associated health costs. The addition of osteoinductive 
factors or osteoprogenitor/stem cells may improve bone repair, particularly in 
osteoporotic conditions, characterized by an impaired healing response [7-10].  
Oral administration of Strontium (Sr) ranelate has shown effectiveness in the 
prevention of both vertebral and non-vertebral osteoporotic fractures [11, 12]. Unlike 
other anti-osteoporotic agents widely used in clinical practice, such as 
bisphosphonates, estrogen, selective estrogen-receptor modulators (SERMs) and 
calcitonin, which inhibit bone resorption [9], Sr ranelate also promotes bone 
formation [13-16]. Several in vitro studies show that Sr ranelate decreases bone 
resorption, by reducing osteoclast activity [13, 14, 17], decreasing functional 
osteoclast markers expression [13], disrupting osteoclasts cytoskeleton [14], and 
increasing osteoclast apoptosis [18]. Simultaneously, it induces positive effects on 
osteoblastogenesis and osteoblast activity in different in vitro models [19], namely by 
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enhancing replication of preosteoblastic cells [14, 20-23], increasing osteogenesis 
[14, 20, 24-26], decreasing osteoblast apoptosis [21, 27], and promoting terminal 
differentiation of osteoblasts into osteocytes [20]. Some pre-clinical studies 
performed in both normal and osteopenic/osteoporotic animal models confirmed 
these in vitro results, showing the beneficial effects of Sr ranelate on bone formation 
and remodeling [28-32]. Despite these important effects, cardiovascular safety of 
orally administered Sr ranelate has been questioned due to a small but significant 
increase in non-fatal myocardial infarctions [12, 33, 34]. Currently, there are strict 
indications and restrictions to its use [12]. 
Nevertheless, Sr incorporation into biomaterials for bone regeneration may improve 
their regeneration potential. In vivo studies showed that doping calcium phosphate 
cements and other ceramics with Sr promotes bone repair [35-37]. A sustained 
delivery system for local release of Sr ions can obviate systemic complications with 
similar rates of bone formation at the site of implantation.  
Current injectable bone defect methacrylate-based fillers have compression 
strengths much higher than that of cancellous bone, and the brittleness of calcium 
phosphate cements is a limitation [38, 39]. We have previously developed various 
types of injectable biomaterials for bone regeneration, namely calcium phosphate 
[40-42] and calcium phosphate/alginate [43] microspheres, as well as different types 
of bio-functional alginate hydrogels [44-47]. When combined, alginate can act as an 
appropriate vehicle for ceramic microspheres delivery and immobilization at the injury 
site. Alginate is a natural linear polysaccharide, biodegradable and biocompatible, 
extensively studied for biomedical applications [48, 49]. Although generally regarded 
as a bioinert material, since it does not elicit specific cell-matrix interactions, grafting 
of alginate with arginine-glycine-aspartic acid (RGD) peptides is an effective strategy 
to provide appropriate guidance signals to promote cell adhesion and facilitate cell 
colonization [50]ENREF_49. Alginate forms hydrogels under mild chemical 
conditions, in the presence of divalent cations, such as Ca and Sr, through a 
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cytocompatible physical gelation process. These cations bind homoguluronic blocks 
in adjacent alginate chains in a cooperative manner (egg-box model) producing a 
cross-linked hydrogel network [51, 52].  
Recently, we developed an injectable hybrid system that consists of ~500 µm 
diameter hydroxyapatite (HAp) microspheres doped with Sr, embedded in a 
functionalized alginate matrix cross-linked in situ with Sr [53]. As a vehicle for the 
microspheres delivery, functionalized alginate with RGD peptides was used, 
providing a scaffold for cell adhesion and migration and allowing for the injectability 
of the system. However, the use of hydrogels in bone tissue engineering is limited by 
low mechanical properties and the non-applicability in load-bearing conditions [54]. 
The packing of the microspheres upon delivery raises the compression strength of 
the material [53], and alginate creates an interconnected 3D network adequate for 
the invasion of blood vessels and cells [55]. Moreover, the presence of Sr in both 
components of the system provides two different release routes upon degradation of 
the materials. This system presents a clinically relevant compromise between 
adequate injectability and gelation time and final compression strength [53]. 
Moreover, in vitro studies showed that this Sr-hybrid scaffold promotes sustained 
release of Sr2+, supports human mesenchymal stem cells adhesion, survival and 
osteogenic differentiation, and inhibits osteoclasts differentiation and activity, as 
compared to a similar Sr-free system [56].  
In the current study we aim to evaluate the in vivo response to the designed Sr-rich 
hybrid system and its influence on new bone formation using a rat metaphyseal 
femoral critical-sized defect model, compared to a similar Sr-free material. The 
proposed system is expected to provide an adequate therapeutic approach to fill-in 
bone defects by minimally invasive surgery, while acting as a scaffold for local Sr2+ 
release to promote bone regeneration. 
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Results 
Radiographical analysis of bone and biomaterial  
A cylindrical defect with 3 mm diameter and depth of approximately 4 mm was drilled 
in the lateral condyle of the right femur (Figure 1A). The defect was filled with the 
biomaterial, injected using a 1 mL syringe (Figure 1B, C). A picture of the Sr-hybrid 
material used is shown in Figure 1D, where spherical particles (Sr-HAp 
microspheres) are embedded within a transparent hydrogel (Sr cross-linked RGD-
alginate). 
 
Figure 1. In vivo intraoperative setting. Critical sized defect created in the distal femur (A). Injection of 
the hybrid material using a 1 mL syringe (B) and filled defect (C). Detail of the hybrid system, composed 
of HAp microspheres embedded in a RGD-alginate hydrogel (D).  
 
Rat femurs were imaged by X-ray along the experimental period allowing for a follow-
up at 15 and 30 days. Representative images of defects filled with materials (Sr-
hybrid or Ca-hybrid) or empty defects are shown in Fig. 2. In hybrid-filled defects 
(Fig. 2A to D), microspheres are located inside the created bone defect (arrows in 
the images), where the higher radiopacity of the HAp microspheres allowed for the 
easy monitoring using X-ray. Microspheres were homogeneously distributed within 
the defects (Fig. 2A to D) and were still detected at day 30, a non-invasive mid-term 
follow-up (Fig. 2B and D). Empty defects were also imaged (Fig. 2E and F) and the 
defect could still be observed after 30 days, confirming it to be of a critical size.  
 
Injectable	hybrid	system	for	strontium	local	delivery	promotes	bone	regeneration	in	a	rat	critical-sized	defect	model	
	 119 
 
Figure 2. Radiographic imaging follow-up. Representative lateral X-Ray images from right rat femurs of 
Sr-hybrid (A and B) or Ca-hybrid-filled (C and D) and empty (E and F) defects at 15 days (A, C and E) 
and 30 days (B ,D and F) post-surgery. Arrows pinpoint site of created defect, filled or empty. 
Microspheres can be observed as circular objects more radiopaque than bone. 
 
Micro-CT morphometric 3D evaluation 
Micro-CT analysis was performed 60 days post-implantation (Fig. 3) to evaluate new 
bone formation at the defect site and to assess the spatial distribution of ceramic 
microspheres within the lesion. In Sr-hybrid filled defects (Fig. 3A), microspheres 
were homogeneously distributed inside the defect with no apparent degradation, with 
preserved size and without modifications in shape. Similar results were found in Ca-
hybrid filled defects. Furthermore, and particularly in Sr-hybrid samples, centripetal 
bone colonization could be observed by new bone formation surrounding the ceramic 
microspheres and with the development of new bone trabeculae in the periphery of 
the defect. 3D morphometric analysis was performed using five femurs per group, 
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where the ROI was defined in binary images (Fig. 3B) and the percentage of new 
bone formed (bone volume fraction, BV/TV) was calculated. Values of (31.5±1.7) % 
and (28.6±1.1) % (BV/TV (%), mean±SE) of new bone was measured in animals that 
received the Sr-hybrid and Ca-hybrid materials, respectively (Fig. 3C). 
 
Figure 3. Micro-CT analysis of distal femur after 60 days of implantation. 3D reconstructed image and 
respective orthogonal slices of micro-CT acquisition of the femur with Sr-hybrid filled defect (A). 
Morphometric analysis approach used to quantify new bone formation: transversal micro-CT slice of a 
femur injected with Sr-hybrid after 60 days of implantation highlighting ROI (B). C - New bone formed 
(BV/TV, %) after 60 days of implantation of Sr-hybrid and Ca-hybrid materials. Data presented as box-
plot with median and min to max whiskers of n = 5 samples (n.s. – statistically non-significant).  
 
Histological evaluation of bone/biomaterial interface 
In Fig. 4A representative images of femurs with defects filled with Sr-hybrid or Ca-
hybrid materials, at days 15 and 60, are portrayed. A global view of the defects and 
materials (Fig. 4A a to d), as well as a more detailed view of the periphery of the 
defect (Fig. 4A a’ to d’ and magnifications a’’ to d’’), are given. Histological analysis at 
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day 15 post-implantation showed that the created defects exhibited similar diameter 
and were filled with approximately 15 to 18 microspheres (Fig. 4A a, b). As early as 
15 days post-implantation, all animals showed, to some extent, newly formed bone at 
the periphery of the defect (Fig 4A a’, b’). Sr-hybrid implanted defects also showed 
new bone formation in close contact with the microspheres, distant from the 
periphery of native bone (Fig. 4A b’’, arrow). SEM images and EDS analysis of this 
newly formed bone in close vicinity of the microspheres is shown in Fig. 4B. The 
results confirmed the high content of calcium and phosphate, and a Ca/P ratio in 
accordance with normal bone composition (Z1 in Fig. 4B), and different from the 
elemental analysis of the microspheres (Z2 in Fig. 4B), where Sr was also identified.  
After 60 days, new bone formation at the periphery was observed in both materials. 
Sr-hybrid implanted defects exhibited a thicker trabecular bone structure at the 
periphery of the defect (Fig 4A d’, d’’), when compared to the Ca-hybrid group (Fig. 
4A c’, c’’). The quantification of new bone formed at the periphery of the defect 
revealed a statistically significant thicker bone structure in Sr-hybrid group (662.4±48 
µm) in contrast to a thinner bone formation (381.1±29 µm) in the Ca-hybrid group 
(mean±SE, p<0.001, Fig. 4C).  
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Figure 4. Histological evaluation of bone/biomaterial interface in femurs implanted with Sr-hybrid and 
Ca-hybrid systems. Coronal histological sections of critical sized defect created in the distal femur, 15 
and 60 days post-implantation (A). Global view of the created defects filled with Ca-hybrid (a and c) and 
Sr-hybrid (b and d) materials, at 15 (a and b) or 60 days (c and d) post-implantation, stained with MT (a 
to d, dashed yellow line circling the created defect area). Interface bone/biomaterial, 15 days (a’ and b’) 
and 60 days (c’ and d’) post-implantation, with Ca-hybrid (a’ and c’) and Sr-hybrid (b’ and d’) systems, 
and higher magnification of square (a’’ to d’’, collagen/bone in blue, yellow dashed line – 
bone/biomaterial interface, * – alginate, M – microspheres, black arrows – new bone). B - SEM image of 
histological section of Sr-hybrid filled defect 15 days post-implantation with EDS spectra of new bone 
(Z1) found near the microsphere and microsphere (Z2). C - Thickness of peripheral bone found around 
the defect (as represented with arrows in A c’’ and A d’’), 60 days post-implantation of Sr-hybrid and Ca-
hybrid systems. Data presented as mean±SEM of 20 different random locations of trabecular bone 
found around the defect of n=5 animals/group, 3 sections/animal, Asterisks show statistically significant 
differences (*** p<0.001).  
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Histological evaluation of the center of the defect 
Representative images of the center of the defect in both groups are shown in Fig. 
5A. Although no evident differences were observed in the diameter of the 
microspheres with time of implantation, alginate showed different behavior between 
groups. After 15 days, some alginate was observed surrounding microspheres in 
both experimental groups (Fig 5A, a and b). In Sr-hybrid group, higher cell invasion 
at the center was observed, mainly of polymorphonuclear neutrophils (PMN) (Fig 5A, 
b and b’). 
 
 
Figure 5. Histological analysis of the center of the defect in femurs implanted with Sr-hybrid and Ca-
hybrid systems. Detailed view of the center of the defect implanted with Ca-hybrid (a and c) and Sr-
hybrid (b and d) materials, stained with H&E, after 15 (a and b) and 60 days (c and d) of implantation, 
with higher magnification of square (a’ to d’, A). B - Area of residual material (microspheres and 
alginate) found within the defect area, 60 days post-implantation of Sr-hybrid and Ca-hybrid systems. 
Measurements were performed by delimiting the area of material in MT stained sections using ImageJ 
software, n=5 animals/group, 3 sections/animal. Data presented as mean±SE and asterisks show 
statistically significant differences (*** p<0.001). C – TRAP-LG staining images of Ca-hybrid (a) and Sr-
hybrid (b) systems filled defects, 60 days post-implantation. (M – microspheres, * – alginate, PMN – 
Polymorphonuclear neutrophils, GT – Granulation Tissue, BV – blood vessels, red arrows – 
Osteoclasts). 
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After 60 days, alginate was still present in both groups (Fig. 5A, c and d), although 
higher degradation was observed in Sr-hybrid filled defects. A statistically significant 
decrease in the area of residual material (alginate + microspheres) present on the 
defect site was observed in Sr-hybrid group with an area of 1.77±0.2 x105 µm2 
compared to 3.14± 0.1 x105 µm2 in Ca-hybrid group (mean±SE, p<0.001, Fig. 5B). 
In a detailed microscopic analysis of the center of the Sr-hybrid filled defects (Fig. 
5A, d and d’) granulation tissue could be observed, with the presence of blood 
vessels (Fig. 5A d’) and osteoclasts (Fig. 5C b). In contrast, in Ca-hybrid group 
osteoclasts were found only at the periphery of the defect (Fig. 5C a). Furthermore, 
PSR staining images under conventional light (Fig. 6A a and c) showed the presence 
of collagen (in red) within the area of the defect in Sr-hybrid (Fig. 6A c) at a higher 
extent than in Ca-hybrid filled defect after 60 days (Fig. 6A a). The use of PSR-
polarization method (Fig. 6A b and d) allowed for the quantification of different types 
of collagen fibrils, i.e. green and red, which are associated with thin/immature/type III 
and thick/mature/type I collagen, respectively. The quantification was performed 
within the central area of the defect using a fixed ROI (diameter=2.4 mm, yellow 
circle in Fig. 6A b and d) and results are shown in Fig. 6B. As expected, an increase 
in the percentage of red/type I collagen was observed from day 15 to day 60 in both 
groups. However, 60 days post-implantation, a slightly higher percentage of red/type 
I collagen was measured in the central defect region in Sr-hybrid group ((3.3±1.3) %, 
mean±SE) compared to Ca-hybrid group ((1.9±0.3) %, mean±SE). 
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Figure 6. Quantification of birefringent collagen fibers by PSR-polarization method in the center of the 
defect. PSR staining visualized under conventional light (a and c) and polarized light (b and d) to identify 
different collagen fiber types, 60 days post-implantation of Ca-hybrid (a and b) and Sr-hybrid (c and d) 
systems (A). PSR stains collagen in red (conventional light) and collagen fibers are specifically 
birefringent in polarized light (green - thin fibers/type III; red - thick fibers/type I, MosaicX image, original 
magnification 20x). Fixed region of interest (ROI) used for quantification is demonstrated in b and d. B - 
Quantification of area of green or red birefringent collagen fibers in the center of the defect in Sr-hybrid 
and Ca-hybrid filled defects, 15 and 60 days post-implantation. Data presented as mean±SE of n=5 
animals/group, 3 images/animal. Asterisks show statistically significant differences (p<0.05) between 
groups for red collagen data. 
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Evaluation of Sr systemic effect 
Sr levels were quantified in serum (Fig. 7A) and organs (Fig. 7B) associated with 
excretory/filtration functions, such as liver, spleen and kidneys, by ICP-AES analysis, 
to evaluate the safety of the designed Sr-hybrid system. The Sr levels in serum of 
animals that were subjected to Sr-hybrid implantation (27.05±2.7 µg/L after 15 days 
and 20.61±1.3 µg/L after 60 days) were not statistically different from those in empty 
defect animals (27.26±3.9 µg/L after 15 days and 23.31±1.9 µg/L after 60 days) or 
non-operated animals (28.59±0.8 µg/L, mean±SD). Even after 60 days of 
implantation, no increase in Sr was found in serum (Limit of quantification, LOQ – 5 
µg/L).  
Sr quantification in organs at 60 days post-implantation supports results from 
measurements in serum. No statistical significant differences were observed 
between empty defect animals (0.44±0.1 µg/g kidney, 0.50±0.1 µg/g spleen, 
0.48±0.3 µg/g liver, mean±SD) and Sr-hybrid group (0.69±0.3 µg/g kidney, 0.59±0.2 
µg/g spleen, 0.36±0.1 µg/g liver, mean±SD). Moreover, histomorphological analyses 
were also performed in histological sections of organs after 60 days (Fig. 7C). In Sr-
hybrid implanted group no morphological alterations at macro or microscopic level 
were observed, when compared to non-operated animals. Analysis of Ca-hybrid 
group presented similar results, with no alterations observed.  
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Figure 7. Strontium systemic evaluation. Strontium concentration found in serum in non-operated, 
empty and Sr-hybrid implanted animals at days 15 and 60 post-surgery (A). Data presented as 
mean±SD of 6 samples/group/time point and 2 samples non-operated. Strontium concentration found in 
the liver, kidneys and spleen of animals implanted with Sr-hybrid and empty defect, 60 days post-
surgery (B). Data presented as mean±SD of 4 samples/group/time point. Representative histological 
sections from liver (a to c), kidney (d to f) and spleen (g to i) of non-operated (a, d and g), Sr-hybrid (b, e 
and h) and Ca-hybrid implanted (c, f, and i) animals, 60 days post-surgery (C). 
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Discussion 
In this study the in vivo response to an injectable Sr-rich hybrid system, composed of 
Sr-doped HAp microspheres embedded in an Sr-cross-linked RGD-alginate 
hydrogel, as compared to a similar Sr-free system (Ca-hybrid material), using a rat 
metaphyseal femoral critical size defect model, is presented.  
The designed hybrid system aims at providing adequate mechanical support in the 
early phases of bone formation and gradual replacement of the artificial scaffold by 
newly-formed bone with adequate function and mechanical properties. The use of 
hydrogels is a promising approach in skeletal regenerative medicine [49, 57-59]. 
Alginate has been used due to its biocompatibility, low toxicity, and mild gelation in 
the presence of divalent cations. Therefore alginate gels act as a natural extracellular 
matrix mimic which can be tuned to deliver bioactive agents and cells to the desired 
site, creating space for new tissue formation and control the structure and function of 
the engineered tissue [49]. Other works have incorporated alginate in self-setting 
cements, for improving injectability, cohesion and compression strength [60-62]. In 
the present study, the ability of alginate to form hydrogels in situ acting as a carrier 
for HAp microspheres under cytocompatible conditions, was explored. In agreement 
with our previous results [53], the system showed to be adequate for minimally 
invasive implantation. A conventional syringe can be used to manually inject the 
material, perfectly filling complex defects and, once set, creating a 3D matrix with 
homogeneous distribution of microspheres. Furthermore, alginate was modified with 
RGD peptides to provide biological cues for promoting cell adhesion and colonization 
[50, 63]. The main disadvantage regarding load-bearing application is alginate low 
mechanical properties which can be overcome through the reinforcement with 
ceramic components, application in non load-bearing areas, and the concomitant use 
of fixation devices [54]. With an alginate-to-microspheres weight ratio of 0.35, and 
microspheres with average diameter of 530 µm, the hybrid system allows for a good 
compromise between mechanical resistance and adequate space between particles 
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(approximately 220 µm), which is expected to facilitate in situ cell colonization and 
invasion by blood vessels [53, 55].  
Deficient bone healing is expected to occur, especially in osteoporotic conditions. 
The use of crystalline HAp in the microspheres, with low degradation rate, ensures 
its permanency at the injury site for longer periods post-implantation, therefore 
allowing for a mechanical reinforcement of the defect. In this work, the high 
radiopacity of microspheres allowed for an easy follow-up in vivo of the material 
using conventional radiological imaging. In clinical practice, this comes as highly 
advantageous since regular X-rays are required to assess bone healing.  
In this system we used alginate cross-linked by internal gelation with Sr2+ as a 
vehicle for the Sr-doped HAp microspheres. Sr was incorporated both in the hydrogel 
and the microspheres, which present different release kinetic profiles resulting in 
sustained Sr2+ release for long periods of time (AH Lourenço et al, unpublished 
results). In other in vivo studies, Sr has been found to enhance bone formation [35, 
37, 64, 65]. For example, Banerjee et al. studied the effect of doping ß-TCP with 
MgO/SrO on bone formation in Sprague-Dawley rats [64]ENREF_59. Doped ß-TCP 
promoted more osteogenesis and faster bone formation than pure ß-TCP. In critical 
calvaria defects of an ovariectomized rat model, macroporous Sr-substituted 
scaffolds showed superior osteoinductive activity to enhance early bone formation, 
and could also stimulate angiogenesis compared with calcium silicate scaffolds [65]. 
The current study showed that Sr-hybrid system presents bioactive properties, 
promoting cell migration, implant vascularization and supports bone ingrowth. Newly 
formed bone developed in close contact with the material, without any fibrous 
interface, growing in a centripetal manner, in continuity with the surrounding host 
trabecular bone, indicates a good integration with the host tissue. Newly formed bone 
percentages is in agreement to those observed in other works testing similar 
materials [66, 67] and a trend towards greater new bone formation was observed in 
Sr-hybrid filled defects.  
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Major histological differences were observed between the two groups. Higher cell 
invasion was seen at the center of the Sr-hybrid filled defects at 15 days post-
implantation, with the presence of polymorphonuclear neutrophils (PMN). Bone injury 
elicits an inflammatory response that is beneficial to healing when acute and highly 
regulated. Inflammatory cells are recruited to the site of injury for clearance of 
pathogens and maintenance of bone homeostasis [68]. This higher cell invasion 
correlates with higher material degradation and bone tissue formation seen after 60 
days. We may assume that Sr induces faster bone healing, possibly due to a faster 
resolution of inflammation, tissue repair and remodeling. This can be appealing since 
the presence of Sr may be modulating the inflammatory response, a current trend in 
bone regeneration strategies regarding the development of biomaterials [69-71].  
Earlier bone formation was identified in close contact with the microspheres in Sr-
hybrid system, highlighting higher osteoinductivity when compared to Ca-hybrid 
system which was evidenced by the thicker trabecular bone structure at the 
periphery of the defect observed in Sr-hybrid group 60 days post-implantation. 
Cardemill et al have also found major differences in the topological distribution of the 
formed bone in association with Sr-doped calcium phosphate or HAp granules, 
although both materials showed comparable overall bone formation, when implanted 
in ovariectomized and non-ovariectomized rats [72]. A larger amount of mineralized 
bone was observed in the center of the defect in HAp group, mainly in 
ovariectomized rats, whereas at the periphery of the defect the bone area was higher 
using Sr-doped granules, irrespective of ovariectomy.  
Granulation tissue with blood vessels and increased collagen deposition were 
observed at 60 days post-implantation in Sr-hybrid filled defects. Several studies 
have correlated the color of birefringent collagen fibers under polarized light with 
different collagen types [73, 74]. Our results show an increase in thicker red collagen 
fibers in Sr-hybrid group. These fibers are associated with type I collagen, the main 
type found in bone tissue. It has been shown that the incorporation of Sr in 
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biomaterials may decrease the number of osteoclasts significantly, but these were 
nevertheless closely associated with newly formed trabeculae, indicating activated 
bone remodeling [75]. A quantitative analysis of TRAP positive cells was not 
performed. However, the presence of osteoclasts in the center of the defect supports 
the higher bone remodeling found in the Sr-hybrid group. Although the microCT 
calculations did not reveal a statistically different bone volume, these histological 
findings sustain the evidence of an improved response with the Sr enriched material. 
The use of methylmethacrylate embedding histological technique allowed for the 
study of both bone and material without decalcification. The technique was optimized 
in our lab [76] using an exothermic process. One of the disadvantages of the 
procedure is the inability to perform immunohistochemistry studies due to loss of 
antigenicity, which is worth exploring in future works.  
With the use of Sr releasing systems, cardiovascular safety is of concern. Current 
guidelines indicate that orally administered Sr ranelate should be avoided in patients 
with past or present history of ischemic heart disease, peripheral arterial disease 
and/or cerebrovascular disease or uncontrolled hypertension, due to an observed 
increase of cardiovascular events [12]. Although previous reports have shown that 
ionic Sr can be added to calcium phosphates and ceramics, potentially stimulating 
bone formation locally, the risk of systemic adverse effects has been rarely reported. 
Baier et al studied the addition of Sr to calcium-phosphate cement in a distal 
methaphyseal femoral defect in ovariectomized rat model. Results have shown faster 
osteointegration of the implant with the addition of Sr, and Sr serum concentrations 
of 10.87 ± 4.16 µg/l were found 1 month post-implantation [35]. The systemic Sr 
levels were very low when compared to those found upon oral Sr ranelate treatment 
[77]. In the present study, Sr concentration was assessed both in the serum and 
organs with excretory/filtration functions, as well as the histology of these organs. 
Serum Sr concentration in operated animals was found to be similar to non-operated 
and in the same range as previously reported [35]. No statistically significant 
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difference was observed between Sr-hybrid implanted and empty defects, both in 
serum and organs. Similarly, Sr concentration levels do not seem to be increased 
compared to normal levels found in the liver of Wistar rats (~0.2 ug/g of dry weight 
[78]) . These results, together with the absence of morphological changes in 
histological sections of the organs suggest that Sr release is restricted to the defect 
site, corroborating the safety of this osteoinductive hybrid system. 
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Conclusions 
We evaluated the in vivo response of an injectable Sr-rich hybrid system composed 
of Sr-doped HAp microspheres embedded in Sr-cross-linked RGD-alginate hydrogel 
intended for bone regeneration. Sr-hybrid system led to an increased bone formation 
in both center and periphery of a critical size defect compared to a non Sr–doped 
similar system, where new bone formation was restricted to the periphery. Besides 
promoting earlier new bone formation, Sr-hybrid system was also found to stimulate 
higher cell colonization with increased deposition of thick collagen fibers in the center 
of the defect. Importantly, our results suggest that only local release of Sr from the 
material was obtained, since no statistically significant differences on Sr 
concentration were detected in retrieved organs or serum. Together, these data 
demonstrate that the incorporation of Sr improved the osteoinductive properties of 
the hybrid system leading to higher bone regeneration without inducing detrimental 
side effects currently associated with other Sr-based therapeutic strategies. The Sr-
hybrid material stands as a promising approach for bone regeneration strategies 
through minimally invasive procedures.  
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Materials and Methods 
Preparation of the injectable hybrid materials 
For the preparation of the hybrid system, RGD-alginate was combined with Sr-doped 
hydroxyapatite (HAp) or HAp microspheres and cross-linked by internal gelation with 
Sr or Ca carbonate, respectively (hereafter designated as Sr-hybrid or Ca-hybrid). 
These formulations and methodologies were adapted and optimized from previous 
works using Ca-cross-linked alginate hydrogels [47, 48, 63, 79].  
Ultra-pure (UP) LVG Alginate (Pronova FMC Biopolymers, G content ≥60%, MW 
131±13 kDa) was functionalized with RGD peptides as previously described [63], 
filtered in 0.22 µm Steriflip units (Millipore), lyophilized and stored at -20 °C until 
further use. Endotoxin levels were measured in RGD-modified and non-modified UP 
alginate using the Food and Drug Administration (FDA) approved Endosafe™-PTS 
system (Charles River). The analysis was performed and certified by an external 
entity (Analytical Services Unit, IBET/ITQB) revealing endotoxin levels below 0.1 
EU/mL (EU - unit of measurement for endotoxin activity), respecting the US 
Department of Health and Human Services guidelines for implantable devices. 
Sterile RGD-Alginate was dissolved in 0.9% (w/v) NaCl solution under sterile 
conditions to yield a 4% (w/v) solution, which was thoroughly mixed with an aqueous 
suspension of SrCO3 (Sigma) or CaCO3 (Fluka) at SrCO3/COOH or CaCO3/COOH 
molar ratio of 1.6. A fresh solution of glucone delta-lactone (GDL, Sigma) was added 
to trigger gel formation at a final polymer concentration of 3.5% (w/v) and a 
carbonate/GDL molar ratio of 0.125.  
HAp microspheres were prepared as described elsewhere [42]. Briefly, HAp powder 
(Plasma Biotal) was dispersed in a 3% (w/v) alginate solution (FMC Biopolymers) 
with a ceramic-to-polymer solution ratio of 0.25. The paste was extruded dropwise 
into 0.1 M SrCl2 (Merck) or 0.1 M CaCl2 (Merck) cross-linking solution, to produce 
Sr-HAp or HAp microspheres, respectively. Microspheres were allowed to reticulate 
for 30 min in the cross-linking solution, and were then washed in deionized water, 
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dried and sintered at 1200 °C. Upon sintering, the polymer phase is burned out 
giving rise to a porous network where Sr or Ca ions are incorporate in the ceramic 
particles. Microspheres with spherical shape and diameter of 500-560 µm were 
retrieved by sieving and autoclave sterilized for further use. Sterile microspheres 
were promptly added to the gelling alginate solution to yield 35% in weight of the total 
mixture, thoroughly homogenized and placed in a 1 mL syringe (Terumo) ready for 
extrusion of the material. 
 
Animal surgical procedure 
All animal experiments were conducted following protocols approved by the Ethics 
Committee of the Portuguese Official Authority on Animal Welfare and 
Experimentation (DGAV) – reference no. 0420/000/000/2012. We used a critical size 
metaphyseal bone defect model adapted from Le Guehennec et al [80], as previously 
described [81]. Three months old Wistar Han male rats (Charles River Laboratories) 
with weight ranging from 300 to 400 g were used. Two different experimental groups 
(n=5 animals/group) were analysed: bone defect filled with Sr-hybrid material and 
bone defect filled with Ca-hybrid material (control material). Animals with empty 
defects (n=5) were used as a critical-sized defect model control. Two different time-
points were used, 15 days and 60 days, to evaluate the relationship of inflammation 
and early bone formation, and new bone formation, respectively. Non-operated 
animals (n=2, 60 days) and animas with empty defects were used as control for 
serum Sr quantification and organ histological analysis. The analgesic buprenorphine 
(0.05 mg per kg), was administrated subcutaneously, 30 minutes before surgery. The 
animals were then subjected to volatile anesthesia with isofluorane, in a chamber, 
according to standard procedures of the animal facility (inducing anesthesia with 900 
cc O2 /min, 5% Isofluorane), confirmed by loss of posture and reflexes. Animals were 
then moved to a clean surgery area and anesthesia was maintained along all time of 
surgery with a face mask (300 cc O2 /min, 2.5% Isofluorane). The right knee of each 
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animal was shaved and skin cleaned and disinfected with 70% ethanol. A lateral 
incision was performed and both skin and muscles were retracted to expose the 
articular capsule. After arthrotomy, a cylindrical defect with 3 mm diameter and depth 
of approximately 4 mm was drilled in the anterolateral wall of the lateral condyle of 
the femur. The defect was washed with physiological saline solution and either filled 
with a biomaterial or left empty. All materials were prepared in sterile conditions and 
injected in the femur's critical defect using a 1 mL syringe. Skin and muscle were 
sutured and the animal was placed back in its cage. Animals were observed until 
regaining consciousness. Post-operative care was carried out for 48 hours, where 
analgesics were given (Buprenorphine) in the same dose as before surgery, every 12 
hours, with a subcutaneous injection. Behavior and wound healing were examined 
along time.  
 
Sample collection 
Fifteen and sixty days post-surgery animals were sacrificed. Animals were kept 
under volatile anesthesia (Isofluorane) and blood collection was performed by 
cardiac puncture. Pentobarbital (Eutasil) was administered for euthanizing animals, 
and femurs and organs (liver, left and right kidneys and spleen) were retrieved. Blood 
was centrifuged and serum collected and stored at -80 1234°C until further use. 
Femurs were cleaned from surrounding soft tissue and immediately placed in 10% 
(v/v) formalin neutral solution for 4 days, rinsed in phosphate buffered saline (PBS) 
solution and dehydrated in serial ethanol solutions (50-70%) for 3 days each. Femurs 
were maintained in 70% ethanol at 4ºC until further use. Organs were also placed in 
10% (v/v) formalin solution for 24h and further processed for paraffin embedding.  
 
Radiographic analysis 
Lateral X-ray of femurs retrieved from animals sacrificed at 15 days post-surgery 
were obtained using a radiographic system (Owandy). For the remaining animals, an 
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in vivo lateral X-ray was also performed at 30 days post-surgery, to allow for a follow-
up of defects and materials. 
 
Micro-computed tomography (micro-CT) analysis 
Bone defects and adjacent areas were analyzed using a high-resolution micro-CT 
(Skyscan 1072 scanner). Specimens (n=5, 60 days post-implantation) were scanned 
in high resolution mode, using a pixel size of 19.13 µm and an integration time of 1.7 
ms. The X-ray source was set at 91 keV of energy and 110 µA of current. A 1-mm-
thick aluminum filter and a beam hardening correction algorithm were employed to 
minimize beam-hardening artefacts (SkyScan hardware/software).  
For all scanned specimens, representative datasets of 1023 slices were used for 
morphometric analysis. To quantify new bone formation, a volume of interest (VOI), 
corresponding to the femoral defect volume, was delineated using CTAn software 
(Skyscan Ltd), to enable quantitative analysis to be performed. Binary images were 
created using two different thresholds, 50-255 (corresponding to particles and new 
bone) and 90-255 (just particles), and the respective TV (Total volume) determined. 
The difference between both TV corresponds to the volume of new bone formed 
(Bone volume, BV). Additionally, 3D virtual models were generated using an image 
processing software (ANT 3D Creator v 2.4, SkyScan). The micro-CT threshold was 
first calibrated from a backscattered image with primarily determined quantitative 
histological measurements, which was then applied equally to all samples. 
 
Histological Analysis 
Femurs were dehydrated in 100% ethanol for 3 days, at 4°C, followed by immersion 
in xylol for 24 h and further embedding in methylmethacrylate and processed for 
histological analysis as described elsewhere [76, 82].  
Serial 7 µm coronal slides were retrieved and the intermediate region of the defect 
(1200-1500 µm) was stained with Hematoxylin and Eosin (H&E), Masson’s 
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Trichrome (MT), Picrosirius Red (PSR) and Tartarate-resistant acid phosphatase 
(TRAP)-light green (LG) staining. Briefly, for H&E, undeplastified sections were re-
hydrated in deionized water and incubated in Gill’s Hematoxylin for 6 min and 
counterstained with alcoholic Eosin Y for 1 min. For MT staining, an MT kit (Sigma-
Aldrich) was used according to manufacturer’s instructions in undeplastified sections. 
TRAP staining was performed according to manufacturer using a TRAP kit (Sigma) 
and counterstained with LG 0.1% (v/v) in deplastified section with xylol overnight. 
Sections were visualized under a light microscope (DP25, Olympus) and imaged. For 
PSR staining, sections were deplastified, hydrated in decreasing ethanol gradient to 
de-ionized water, stained for 6 min in Celestine blue and another 6 min in Gill’s 
Hematoxylin. After a 10 min washing step in water, sections were stained with Sirius 
Red for 1 h, washed with acidified water, dehydrated and mounted. Sections were 
imaged through polarization lens under a light microscope (Axiovert 200M, Zeiss) 
using MosaiX software.  
Regarding the retrieved organs, paraffin sections of 3 µm thickness were sequentially 
obtained and stained with H&E. 
Peripheral bone thickness was determined as the average thickness of twenty 
different random locations (arrow in Fig.4A c’’ and d’’) of bone found around the 
defect area using MT stained sections. AxioVision software was used for the 
measurements (n=5 animals/group). The area of residual material found within the 
defect was measured by the same user, manually delimiting the area of the hybrid 
(microspheres and alginate) in MT stained sections. Alginate and microspheres 
retain staining and have a different texture, allowing for the easy identification of the 
material. MosaicJ (ImageJ software, n=5 animals/group, 3 sections/animal) was used 
for the assembly of microscopic images at 20x magnification and area values were 
obtained in ImageJ. 
Birefrigent green and red fibers were quantified as the percentage of thin/type III and 
thicker/type I collagen fibers, respectively [73, 74]. The collagen area within the 
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central region of the defect (diameter=2.4 mm) was quantified in ImageJ software 
(n=5 animals/group, 3 images/animal). Sections were stained simultaneously and 
images acquired in the same day with the same parameters.  
Serial 7 µm coronal slides were also analysed by Scanning Electron 
Microscopy/Energy-dispersive X-ray spectroscopy (SEM/EDS) using a High 
Resolution (Schottky) Environmental Scanning Electron Microscope with X-Ray 
Microanalysis and Electron Backscattered Diffraction analysis: Quanta 400 FEG 
ESEM / EDAX Genesis X4M. Samples were coated with an Au/Pd thin film, by 
sputtering, using the SPI Module Sputter Coater equipment.  
 
Systemic Sr quantification by Inductively Coupled Plasma – Atomic Emission 
Spectroscopy (ICP-AES) 
Sr levels in serum and organs (spleen, liver and kidneys) were quantified by ICP-
AES (Horiba Jobin-Yvon, Ultima spectrometer, generator RF of 40,68 MHz). Serum 
samples (n=6 samples/group/time point and n=2 non-operated) were diluted 5 times 
in 1% Suprapur nitric acid (Fluka) as described elsewhere [83]. Spleen, liver and 
kidneys were digested in Suprapure nitric acid (n=4 samples/group/time point). 
Before use, all glass materials were washed and then immersed in a 20% (v/v) nitric 
acid solution for at least 1 day in order to eliminate possible contaminations with Sr 
or other impurities from the vessels walls. Organs (~300 mg) were dried in a 
microwave (MARS-X 1500 W, CEM) configured with a 14 position carousel. An 
aliquot of 10 mL of Suprapur nitric acid was added and microwave digestion 
proceeded during 55 min, according to microwave digestion program 
(Supplementary - Table 1). The solutions were concentrated until 1 mL and 
preserved at −20 °C until Sr determination. The limit of detection (LOD – 1 µg/L) and 
limit of quantification (LOQ – 5 µg/L) for Sr were adequate for the expected 
concentration range of the samples. 
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Statistical Analysis 
Statistical analysis was performed using non-parametric Mann–Whitney test with 
GraphPad Prism Program. A value of p<0.05 was considered statistically significant: 
*p<0.05; **p<0.01; *** p<0.001.   
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Supplementary Material 
Stages 1 2 3 
Power (W) 600 600 600 
Time (min) 5 10 10 
Temperature (control, ºC) 50 100 175 
Hold (min) 10 10 15 
Table 1. Microwave digestion program 
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This PhD thesis aims to contribute to the development of alternative injectable 
biomaterials, which may be particularly suitable for minimally invasive implantation in 
bone defects of osteoporotic patients. Synthetic biomaterials have been used as 
bone substitutes for decades, and advances in tissue engineering have enabled the 
design of bioactive scaffolds capable of inducing bone formation and vascularization 
[1, 2]. Following previous works of our group, we sought to develop an alternative 
biomaterial suitable for this application. Our specific objectives were: 1) assess the 
current evidence of the benefits and safety of incorporating Sr in bone substitutes, 2) 
develop and characterize a new Sr-enriched injectable hybrid system, and 3) 
evaluate the effect of Sr enrichment in vivo. 
Recently, the focus turned onto the possibility of incorporating different growth 
factors, drugs, genes or stem cells in biomaterials to accelerate and improve bone 
healing [2]. Biomolecules such as growth hormone (GH), transforming growth factor-
β (TGF-β), bone morphogenetic proteins (BMP), insulin-like growth factor (IGF), 
fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF), trace 
elements (zinc (Zn), magnesium (Mg), silicate (Si), and Sr), drugs like zolendronate 
and alendronate, and mesenchymal stem cells, have all shown a positive effect in 
bone healing when added to CaP biomaterials [2-4]. This in situ administration allows 
the scaffold to support new bone formation while the released doping agent induces 
a local tissue specific response, potentially obviating systemic side effects [4, 5]. 
Sr is an obvious candidate for effective scaffold doping due to its dual 
osteoanabolic and anti-osteoclastic activity. An increasing number of publications 
reported on the beneficial effects of incorporating Sr in biomaterials [6-8]. However, 
most are in vitro studies, and the few in vivo reports available generally do not 
present an adequate control group. As such, current literature does not provide 
sufficient evidence on the effectiveness and safety of adding Sr to biomaterials, and 
its use is still a matter of debate. In the context of this thesis we have performed the 
first systematic review that summarizes the in vivo effect of Sr-enriched biomaterials 
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in bone formation and remodeling. In order to accurately define this specific role of 
Sr, we restricted our selection to in vivo original studies comparing at least two 
groups that solely differed in Sr addition to the experimental group biomaterial. Only 
27 papers matched these inclusion criteria. None used a large animal model and a 
single one was performed in humans. Moreover, follow up was variable, but usually 
short, and less than half reported on osteoporosis. Nevertheless, all articles showed 
similar or increased effect of Sr incorporation in bone formation and/or regeneration, 
impacted by time and concentration, supporting the beneficial role of Sr as a doping 
agent. Although there are current restrictions to the use of oral strontium ranelate in 
the management of osteoporosis due to cardiovascular events, surprisingly only 4 of 
the included studies have addressed the systemic side effects of local Sr release [7, 
9-11]. In spite of the apparent absence of significant side effects, additional studies 
are needed to provide an adequate clarification on this matter.  
This review also points to the lack of specific guidelines for evaluation of 
substitute biomaterials. Therefore, studies with different methodologies and 
strategies to assess Sr effect compromised a reliable quantitative synthesis and 
analysis of data. Different size, location and type of defect, animal species, and 
measurement protocols can all impact results and preclude direct comparisons [12]. 
Relevant and consistent healthy as well as diseased bone defect models, and clearly 
defined evaluation methodologies are needed for both translational preclinical and 
clinical future studies [12, 13]. 
The hybrid injectable viscoelastic system presented in this thesis is based on 
previous works from our group on the development of different types of microspheres 
and hydrogels [14-22]. Unlike traditional block scaffolds, small particles can be 
combined with appropriate vehicles to be administered through minimally invasive 
surgery. These injectable hybrid biomaterials can easily conform to irregular defects, 
while assuring space between particles for tissue and vascular ingrowth, as required 
for effective healing. In previous works ceramic microspheres and biocompatible 
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polymeric solutions were studied and optimized to produce an adequate injectable 
bone filler [21, 23]. The injectability of this system, consisting of hydroxyapatite 
microspheres and an alginate vehicle with in situ gel-forming ability, was also 
evaluated [24].  
Based on these results, we intended to develop an alternative biomaterial, not 
only to be injected and fill defects of any size and shape, but also to elicit an 
improved healing response. Sr was incorporated in both the microspheres and the 
vehicle, allowing different release rates, due to both faster degradation kinetics of the 
polymer network and a slower one of the ceramic particles. Accordingly, besides 
offering structural support for cell migration and tissue ingrowth, the hybrid system 
enables a continuous Sr release, that begins at the early stages of implantation. An 
improvement in the effectiveness of bone regeneration is therefore expected, 
especially useful in osteoporotic conditions. 
In Chapter III we have described the process of development and 
characterization of the biomaterial. Besides mechanical properties, we sought to 
develop a system that could be easily handled in any operating room, with adequate 
working time and manual injectability. We observed that the incorporation of Sr in the 
microspheres almost doubles their rupture force. Also, when Sr is used as the 
reticulating agent, the extrusion force is smaller, allowing for an increase in alginate 
concentration and percentage of microspheres, leading ultimately to an improvement 
in mechanical properties. The best compromise between injectability and 
compression strength was obtained with a hybrid system of 3.5% alginate cross-
linked with Sr, and 35% of Sr enriched microspheres. However, the elastic modulus 
is still below that of cancellous bone [25, 26]. Thus, the system appears more 
adequate for use in non load-bearing regions, or combined with internal fixation 
devices. Nevertheless, reports on the mechanical properties of hydrogel/calcium 
phosphate composites are scarce, and our results are an important addition to the 
existing literature [27]. Other adjustments, as the number of cross-links, type of 
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monomer and local environment, are available strategies in order to fine-tune the 
alginate hydrogel biochemical and viscoelastic properties. Additionally, 
biomechanical tests were performed with unsterilized ultra pure alginate, and the 
impact of sterilization in the biomaterial needs further assessment. 
The use of alginate, combined with ceramic microspheres not only works as a 
carrier but also allows improved cohesion and resistance to wash out as the polymer 
forms a gel in situ [27, 28]. In our in vivo study, a conventional syringe was used to 
manually inject the material, perfectly filling the defect. Radiographic analysis 
showed a homogeneous distribution of microspheres, which remained in place for 
the full duration of the experiment. 
Microspheres have a uniform shape and diameter, adequate for effective bone 
substitution [29], and are homogeneously distributed within the hybrid system.  
Although alginate is a non cell-interactive polymer, RGD-grafting promotes 
osteogenic cell adhesion, focal adhesion formation, proliferation, and differentiation, 
and progressive degradation [30], leaving an appropriate space between particles for 
blood vessels invasion and cell colonization [31].  
In Chapter IV we investigated the in vivo response to this novel hybrid system 
in a critical size defect model. Both Sr-hybrid and Sr-free hybrid systems induced 
newly formed bone percentages comparable to those reported in other works testing 
similar materials [32, 33]. However, there were significant histological differences 
between these groups. Sr incorporation promoted earlier new bone formation and 
greater cell colonization, with increased deposition of thick collagen fibers in the 
center of the defect, leading to increased bone formation in both center and 
periphery of a critical size defect. These results emphasize the impact of Sr-doping in 
improving bone remodeling. One can speculate that this may be due to a role of Sr in 
the modulation of the inflammatory response. 
Another important finding was the absence of significant differences in Sr levels 
both in serum and excretory/filtration organs between animals with Sr-hybrid 
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implanted and empty defects. Although the evidence on the effectiveness of Sr-
doping is mounting, safety is still a concern, as previously stated. This work provides 
additional evidence on this topic, but future studies should focus on this important 
problem. 
Testing our system in a clinical setting would be important. Due to logistic and 
cost constrains an osteoporotic model was not tested in the present thesis. As 
evidenced by our systematic review, osteoporosis may influence the impact of Sr 
doping, and such study should be undertaken. Besides, no appropriate study has yet 
been carried out in large animal models, and only one has been reported on humans 
[34]. Further studies on these settings are of upmost importance in the translation of 
this system to the daily clinical practice.  
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Conclusions 
In conclusion, this thesis presents an alternative viscoelastic hybrid system for 
the management of bone defects, composed of an alginate matrix cross-linked in situ 
with Sr, and Sr-rich HA microspheres. The reasoning for this strategy lies in the 
growing evidence of the beneficial effect of Sr enrichment of biomaterials, which was 
confirmed in the systematic review conducted. This system can be manually injected, 
sets in situ and offers structural support, providing a temporary scaffold for bone 
growth. In a critical-size rat femoral bone defect model, we observed that Sr 
incorporation promoted earlier new bone formation and greater cell colonization, with 
increased material degradation and deposition of thick collagen fibers in the center of 
the defect, leading to increased bone formation in both center and periphery of the 
defect. Moreover, no changes were observed in Sr levels both in systemic organs 
and serum. This Sr-hybrid injectable biomaterial stands as a promising approach for 
bone regeneration. 
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